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ABSTRACT OF DISSERTATION

APOE AS A METABOLIC REGULATOR IN HUMANS, MICE, AND ASTROCYTES
Altered metabolic pathways appear to play central roles in the pathophysiology of
late-onset Alzheimer’s disease (AD). Carrier status of the E4 allele of the APOE gene is
the strongest genetic risk factor for late-onset AD, and increasing evidence suggests that
E4 carriers may be at an increased risk for neurodegeneration based on inherent metabolic
impairments. A new appreciation is forming for the role of APOE in cerebral metabolism,
and how nutritional factors may impact this role. In chapter 1, the literature on nutritional
interventions in E4 carriers aimed at mitigating disease risk is reviewed. Studies
investigating the mechanism by which E4 increases disease risk have focused primarily on
the association of E4 with the neuropathological hallmarks. While these studies have aided
in our understanding of the role of E4 in late-disease pathology, investigating metabolic
signatures of E4 carriers who have not yet developed neuropathology gives insight into the
potential earlier mechanisms of E4 as a risk factor for AD. For example, an early and
consistent biological hallmark of AD is cerebral glucose hypometabolism as observed by
fluorodeoxyglucose positron emission tomography (FDG-PET). Interestingly, E4 carriers
also display an AD-like pattern of decreased glucose metabolism by FDG-PET far before
clinical symptomology. Since glucose hypometabolism occurs early in AD and early in E4
carriers, it may represent a critical prodromal phase of AD. Beyond this brain imaging
finding, it is unclear if APOE has any other discernable metabolic effects in cognitively
unimpaired young people. In chapter 2 we bridge this knowledge gap in the field. We
utilized indirect calorimetry (IC) as a method for assessing metabolism in young and
middle aged volunteers with and without the E4 allele. While IC is commonly used in
clinical settings to assess nutritional status, it has never been used to assess risk for
cognitive decline. Thus, repurposing IC to study the metabolic effects of an AD risk factor
such as E4 represents a simple, cost-effective, and innovative new approach. We found that
young female E4 carriers show a lower resting energy expenditure compared to noncarriers. We also tested how E4 carriage affects response to a glucose challenge by
administering a glucose rich beverage in conjunction with IC measurements and plasma
metabolomics. We found that female E4 carriers were unable to increase oxygen
consumption relative to non-carriers, reflecting an impairment in glucose oxidation.
Additionally, the plasma metabolome of E4 carriers showed increased lactate and an
overall metabolic profile consistent with aerobic glycolysis. We translated these findings
to mice expressing the human alleles of APOE. We found that E4 mice on a normal chow
diet have lower energy expenditure than E3 mice, a difference further exacerbated by high
carbohydrate diet feeding. Stable isotope tracing in mice whole brains and astrocytes

implicate increased utilization of aerobic glycolysis as a mechanism for altered glucose
handling in E4 carriers. Another pathological feature of the Alzheimer’s brain is glial lipid
accumulation. The mechanism for this is largely unknown. In chapter 3, the literature
pertaining to lipid droplets (LD) in the brain is reviewed. We show that LDs are much more
than simple fat depots, playing critical roles in metabolism, inflammation, and various
neurodegenerative diseases. In chapter 4, the effect of the E4 allele on astrocyte LD
accumulation and turnover is assessed. Using an in vitro model of APOE we probed the
storage and oxidation capacity of fatty acids in E3 and E4 astrocytes. We observed that E4
astrocytes exhibit greater storage of fatty acids as LDs under control and lipid loaded
conditions compared to E3 astrocytes. Furthermore, we found that E4 astrocytes rely on
these LDs as a source of fuel for oxidation. Therefore, APOE appears to regulate whole
body energy expenditure, cerebral glucose oxidation, astrocyte LD metabolism, and risk
for a host of metabolic diseases. In chapter 5, the evolutionary history of APOE is presented
to posit a hypothesis for why E4 may be disadvantageous in modern times compared to its
prior advantages in the pre-historic era. These results point toward a larger role for APOE
in the regulation of metabolism than previously understood and advocates for alternative
nutritional approaches including calorie reduction and intermittent fasting as plausible
interventions to mitigate disease risk in E4 carriers.
KEYWORDS: Alzheimer’s, APOE, astrocytes, metabolism, lactate, energetics
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CHAPTER 1. EFFECTS OF APOE IN NUTRITIONAL METABOLISM IN
DEMENTIA
[This chapter consists of material adapted from a published manuscript: Farmer BC,
Johnson LA, Hanson AJ. Effects of apolipoprotein E on nutritional metabolism in
dementia. Current Opinion in Lipidology. 2019 Feb. PMID: 30550413]
1.1

Introduction
Apolipoprotein E (ApoE) is the major apolipoprotein in the central nervous system,

responsible for lipid transport and cholesterol homeostasis. The gene that encodes ApoE
(APOE) has three human isoforms– E2, E3, and E4 – with population frequencies of 8.4%,
77.9%, 13.7% respectively. The APOE gene has attracted much attention as the strongest
genetic risk factor for the development of late onset Alzheimer’s Disease (AD). Carriage
of the E4 allele substantially raises one’s risk of developing late onset AD, whereas the E2
allele is protective.(1) A new appreciation is forming for the role of APOE in cerebral
metabolism of both glucose and lipid substrates. In this chapter, I will summarize recent
findings in both humans and experimental APOE mouse models.
AD is characterized by several neuropathological hallmarks, including
accumulation of extracellular amyloid plaques, intracellular tau tangles, and metabolic
abnormalities

including

disruption

of

glucose

metabolism

and

mitochondrial

dysfunction.(2) The mechanisms by which E4 carrier status influences or causes these
pathologies are still unclear, but there are likely both amyloid dependent and independent
effects. Although it only differs from E3 and E2 by one or two amino acids, the structure
of apoE4 protein is more compact and unstable which alters its ability to bind lipid, and in
turn bind and clear amyloid breakdown products from the brain. The E4 isoform also
appears to alter mitochondrial function, interfere with insulin signaling, and increase lipid
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oxidation.(2) E4 carriers also demonstrate more pronounced and earlier defects in cerebral
glucose metabolism.(3, 4) The effects of E4 are numerous, and many of the pathologies
appear to involve cerebral energy metabolism, suggesting nutritional interventions could
delay or prevent cognitive decline in these individuals.(4)

1.2

APOE influences the connection between diet and brain health
Abundant epidemiologic evidence shows high fat diets (HFD) and resultant

metabolic abnormalities such as obesity and insulin resistance are risk factors for AD.(5,
6) Importantly, these findings are often modulated by APOE genotype. The association
between HFD and AD in human epidemiological work is limited to E4 non-carriers in
some(7, 8) but not all studies.(9) For example, we showed that acute high fat feeding
improved cognition and plasma AD biomarkers in E4 carriers, but worsened these
biomarkers in E4 non-carriers.(10) Reasons for this paradoxical response to HFD in E4
carriers is unknown, and could involve differences in transport of macronutrients,
differences in lipidation status of the apoE protein, or differences in insulin and glucose
metabolism.(2, 11, 12)
One major consequence of HFD is peripheral insulin resistance, which decreases
brain insulin transport and subsequent function.(13) Both E4 carriers and non-carriers with
AD have reduced CSF insulin and demonstrate signs of brain insulin resistance. However,
the relationship between peripheral and brain insulin, and the connection between insulin
resistance and brain aging, is less established in E4 carriers.(14-16) Similarly, E4 status
influences the correlation between Aβ and insulin resistance. Only E4 non-carriers showed
a correlation between CSF Aβ and CSF:plasma glucose ratio,(15) and showed reduced
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plasma amyloid and memory improvement after an insulin infusion; E4 carriers had no
changes in memory and their plasma amyloid increased in response to insulin.(17)
Additionally, in an acute meal study, E4 non-carriers showed an increase in plasma Aβ42
after a high-fat meal compared to a high carbohydrate meal. Conversely, E4 carriers
demonstrated higher plasma Aβ after the high carbohydrate meal accompanied by larger
changes in insulin.(10)

Given the brain insulin dysfunction in AD patients, insulin

sensitizers and intranasal insulin are being investigated as treatments, and although the data
are mixed, and the majority of these treatments improve cognition only in E4 noncarriers.(12)
Promisingly, healthy diets and certain nutritional factors improve cognition and
reduce AD risk, but these findings are also influenced by APOE genotype. Perhaps the best
studied diet for AD prevention is the Mediterranean (MeDi).(18) Most studies which have
demonstrated cognitive or AD biomarker benefits of MeDi included APOE genotype as a
covariate.(19-21) However, few if any have done pre-specified subgroup analyses by
APOE status. A multicomponent interventional study involving a diet similar to MeDi
showed that 2 years of a healthy Nordic diet (abundant fish, fruits and vegetables), exercise
and brain training can prevent cognitive decline, although adherence to diet was not tracked
and the control group also received information about the diet.(22) A subgroup analysis
revealed that E4 carriers benefited more on tests of cognition from this intervention.(23) In
another study, a hybrid Mediterranean diet was found to be protective against incident AD,
but less protective in E4 carriers.(24)
Seafood intake is another dietary pattern associated with slower cognitive decline,
but in one study this finding was only noted in E4 carriers.(25) Seafood contains high levels
3

of polyunsaturated fatty acids, or PUFAs, including DHA and EPA, and high intake of
these nutrients is protective against AD. Despite the stronger protective effect of seafood
in E4 carriers, studies specifically examining PUFAs show more benefit in non-carriers.
In an intervention study in older adults, E4 non-carriers who received DHA for 18 months
declined significantly less on a cognitive test compared to placebo, whereas DHA had no
effect on E4 carriers.(26) In another study, there was a stronger association between fish
consumption and increased plasma DHA levels in E4 non-carriers, whereas in E4 carriers
there was a positive association between meat and DHA.(27) Follow-up studies have
suggested several potential mechanisms, including decreased lipoprotein lipase activity
and differential fatty acid processing, increased VLDL turnover, or higher levels of lipid
peroxidation and beta-oxidation in E4 carriers.(27, 28) How these peripheral differences
affect brain transport and utilization of PUFAs and other FFA remains unknown. (27, 28)
Since patients with AD have decreased cerebral glucose metabolism, diets and
pharmacologic agents which induce ketosis and supply the brain with ketone bodies are
being investigated as treatments.(29) Although E4 carriers have more pronounced and
earlier cerebral glucose dysregulation, only E4 non-carriers with AD responded to a
ketosis-inducing medium-chain triglyceride supplement. The authors speculated that the
mitochondrial dysfunction in E4 carriers, renders this group less able to use ketone bodies
in lieu of glucose for brain fuel; alternatively there could be differences in ketone body
brain transport.(30)
The evidence continues to accumulate around the idea that APOE genotype
influences cognitive and neurological responses to diet and dietary supplements. To
understand the pathophysiology of diet and dementia risk, in vitro and in vivo mouse
4

models serve as ways to examine these mechanisms more carefully. As noted above, HFD
and resultant metabolic abnormalities have been identified as risk factors for AD.(5, 6)
The saturated FFA palmitate induces inflammation in cell lines and AD animal models.(31,
32) However most human cell lines are studied without respect to APOE status, and the
most utilized rodent models of AD which have provided much of the data for the
experimental link between dietary factors and AD pathology are analogous to E4 noncarriers.(33) However, new models of human induced pluripotent stem cells (iPSC) edited
to include APOE3 and APOE4 hold promise, and recent studies have demonstrated
important differences in function with respect to lipid and cholesterol metabolism in
neuronal- and glial-derived iPSCs.(34) In the next sections we will discuss how humanized
APOE mice can help us better understand the differences we are seeing in vivo, in particular
the response to high fat diets and lipid-based therapies in E4 carriers.

1.3

Knowledge and tools available to study APOE effects on nutritional metabolism in
dementia
Research into the effect of APOE on nutritional metabolism has often relied on

mouse models as a correlate for human disease. While several mouse models of human
APOE exist (Table 1.3.1), the most widely used are the targeted replacement (TR) mice
developed by Sullivan et al in the laboratory of Dr. Nobuyo Maeda. These mice were
created by mating C57BL/6J mice with chimeras whose embryos had been injected with
embryonic stem cells electroporated with human APOE2, APOE3, or APOE4
constructs.(35) The vector was inserted at the normal murine APOE locus to maintain
physiologic expression of the human variant. The metabolic profiles of these mice have
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been explored by many groups, specifically with respect to how they differ from wild type
mice and humans.
While 5-10% of human E2 homozygotes develop type II hyperlipoproteinemia, all
E2 TR mice display features of it, including spontaneous atherosclerosis, xanthomas, and
decreased VLDL clearance.(36) It has been hypothesized that this is due to the low affinity
of E2 for the main VLDL receptor, LDLR. While humans are able to clear VLDL through
apoE independent mechanisms (apoB100-LDLR interactions) mice are wholly dependent
on apoE for clearance, and thus magnify functional differences in the apoE isoforms. While
the abnormal lipid profile confounds studies of E2’s lipid associated role in mitigating AD
risk, the model is still useful for probing alternative roles of E2. For example, some have
posited that E2 provides a metabolic advantage and thereby decreases AD risk. Venzi and
colleagues found E2 mice to exhibit a significant increase in cerebral glucose metabolism
beyond 3 months of age. Compared to E3 mice at 6 months, E2 mice showed increased
glucose uptake by [18F]FDG imaging in whole brain, cingulate cortex, cortex, and
hippocampus and then a global increase at 9 months of age.(37) However, the first
comprehensive human study to examine E2 carriers with [18F]FDG imaging showed that
age-related decreases in glucose uptake did not significantly differ from E3
individuals.(38) Thus, the cerebral metabolic effects of E2 remain an important, but
unsettled issue.
The E3 and E4 TR mice also express their human isoforms at physiologic levels.(35,
36, 39) They are normolipidemic but become hyperlipidemic in response to a westernized
diet.(36, 40) While E4 confers a higher risk of dementia in humans, it is controversial what
cognitive effects are present in in TR E4 mice (in the absence of amyloid or tau over
6

expressing mutations). Rodriguez and colleagues observed impairments in spatial learning
and memory in young E4 TR mice in the Barnes maze test, but no difference in a hidden
platform water maze experiment.(41) In contrast to mixed effects of E4 on behavioral
outcomes and age-related cognitive decline, the association of E4 with cerebral metabolic
changes is more clear. Several groups have demonstrated reductions in cerebral glucose
uptake in E4 mice compared to mice expressing E3 (42-44) – similar to the wellestablished findings via FDG PET in human E4 carriers.
In humans, E4 carrier status is associated with a higher brain amyloid burden, but it
has been more difficult to demonstrate this in E4 mice unless other AD-related genes are
present.(11)

When AD mice are crossed with APOE knockout mice, the resultant

phenotype is less amyloid depositions, suggesting that the apoE protein is necessary for
amyloid breakdown products to cause plaques. AD mice that express human APOE alleles
do recapitulate what is seen in humans with more amyloid in E4 compared to E3, and less
still in E2.(45) One important difference that may affect amyloid burden studies is that
humanized E4 is less stable in mouse brain and is degraded, whereas this does not appear
to be the case in humans.(11, 46)
As glucose uptake and utilization is impaired in E4 carriers and AD individuals,
many groups have studied the insulin-signaling pathway as a potential target of APOE
modulation. Hippocampal RNA from middle-aged female E2, E3, and E4 TR mice was
arrayed for genes involved in insulin signaling. This revealed that E2 mice have higher
levels of Igf1, insulin receptor substrates, and the glucose transporter GLUT4 than E3 and
E4.(47) Furthermore, E4 mice showed a significant decrease in PPAR-gamma and insulindegrading enzyme, pointing to a further compromise of insulin signaling and glucose
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utility. These findings were confirmed by another group who used an array for glucose and
ketone body metabolism and identified glucose transporters and hexokinases were robustly
altered by APOE genotype.(48) The Bu group discovered that E4 restricts insulin receptors
to endosomes and thereby impairs trafficking and signaling, an effect exacerbated by
HFD.(49) To test the effect of APOE on peripheral insulin receptor sensitization, To et al.
fed E3 and E4 mice a diabetogenic diet then treated the mice with a thiazolidinedione. They
found a reduction in tau phosphorylation, but only in E3 mice.(50) These studies support
the idea that E4 renders the brain insulin resistant, likely through regulation of insulin
receptors and glucose transporters.
Despite growing evidence for a role of diet in AD and the potential of personalized
medicine and gene-diet interactions, very few studies have attempted to tackle the
interaction between APOE and diet in the context of AD or cognitive function. Our group
explored the potential interactive effects of diet and E4 on cognition by using a mouse
model of chronic high fat feeding. We found that disruption of glucose homeostasis
following 6 months of HFD led to more pronounced cognitive impairments in E4 compared
to E3 mice. These cognitive deficits were specific to hippocampal-dependent spatial
learning and memory outcomes, and were accompanied by wide-ranging isoform-specific
alterations in the epigenetic landscape and changes in cerebral metabolism.(51) It is
hypothesized that its effects on cerebrovascular function could be the driving force of the
cognitive impairing effects of HFD. We found that E4 mice fed a HFD exhibit reduced
glucose uptake compared to both E4 mice on a control diet and E3 mice on both control
and HFD.(51) Further, E4 carriage and HFD acted synergistically to lower cerebral blood
flow.(43) Interestingly, when challenged with an acute glucose bolus, E4 but not E3 mice
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responded beneficially in terms of both increased blood flow and enhanced performance
in a memory task; hinting at a potential role for APOE in modulating neurovascular
coupling and cognitive function. (43)
In the APP mouse model of distorted amyloid processing, expression of E4 along
with a HFD significantly increases amyloid deposition compared to E3.(52) E4 was also
found to increase amyloid and glial activation in the EFAD model of AD when fed a
westernized diet. (53) E3 mice gain more weight on a HFD, while E4 mice seem to
upregulate genes involved in fatty acid mobilization and utilization in the periphery.(54)
This could parallel a central E4 promoted HFD induced bioenergetic shift toward fatty
acids and away from glucose as the primary cerebral energy source. Together, these studies
show that E4 seems to exacerbate the negative effects of a HFD on cognition.

1.4

Conclusions
As we continue to uncover the role of the APOE gene as a contributor to cognitive

decline, we must take into account the additive effects that the westernized high fat diet
and insulin resistance seem to have on disease progression. Human epidemiologic and
experimental evidence suggests that APOE genotype changes the relationship between
several lipid-related macronutrients and markers of brain health and cognition. Whether it
is diet-induced insulin resistance, PUFAs from fatty fish, or ketone bodies from medium
chain triglycerides, APOE status appears to modulate important responses to lipid-related
therapies. Mouse models have been vital in confirming that E4 exacerbates the negative
cognitive effects of diabetogenic and HFD, and also suggest reasons by which E2 carriers
are less susceptible to developing AD. Future studies should utilize these and other
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experimental models of APOE to implicate specific cells and tissues in the E4 response to
nutritional interventions, and include APOE genotype as an important subgroup for
analysis of human interventions.
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Table 1.1 Summary of APOE Models by Expression and Original Report or Source
Model

APOE Expression

Original Study

Targeted Replacement Mice

Global E2, E3, E4

Sullivan et al. 1997(35)

NSE Promoter

Neuron

Raber et al. 1998(55)

GFAP Promoter

Astrocyte

Sun et al. 1998

Dox Inducible

Cell specific

Liu et al. 2017(56)

APOE* KI mice

Global E2, E3, E4

Jackson Laboratory

hApoE4 Knock-in Rat

Global E4

Horizon Discovery

hApoE Knock-in Fly

Global E3, E4

Haddadi et al. 2016(57)
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CHAPTER 2. APOE4 LOWERS ENERGY EXPENDITURE BY INCREASING FLUX
THROUGH AEROBIC GLYCOLYSIS
[This chapter consists of material adapted from a submitted manuscript that is under
review. For supplementary materials pertaining to this chapter, see appendix 1.]
ABSTRACT
Cerebral glucose hypometabolism is consistently observed in individuals with
Alzheimer’s disease (AD) and also in young cognitively normal carriers of the Ε4 allele of
Apolipoprotein E (APOE). As Ε4 is the strongest genetic predictor of late-onset AD,
identifying other metabolic signatures of young Ε4 carriers may provide insight into
disease mechanisms and early screening criteria for AD. Here, we perform the first
assessment of whole body energy expenditure (EE) in young and middle-aged human
participants with and without the Ε4 allele. Strikingly, young female Ε4 carriers show a
lower resting EE than non-carriers - a phenomenon exaggerated following a dietary glucose
challenge due to stunted oxygen consumption. This Ε4 effect was not observed in middleaged individuals, suggesting an “early-aged” Ε4 phenotype of oxidative impairment. When
given a cognitive challenge, EE increased in all study volunteers, representing a strong
cerebral contribution to EE. Plasma metabolites associated with glycolysis were elevated
in Ε4 carriers and pathway analyses revealed a glucose-induced increase in aerobic
glycolysis (i.e. the Warburg effect). Isotopic tracing of 13C-glucose in mice and astrocytes
expressing human APOE showed Ε4-associated increases in lactate synthesis and
decreased pyruvate entry into the TCA cycle. Finally, E4 astrocytes had elevated glycolytic
activity, decreased oxygen consumption, blunted oxidative flexibility, and a lower rate of
glucose oxidation in the presence of lactate. Together, these results suggest system-level
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metabolic reprogramming in young Ε4 carriers, an endophenotype observable by indirect
calorimetry and plasma metabolomics decades prior to clinically manifest AD.

2.1

Introduction
The Ε4 allele of Apolipoprotein E (APOE) confers more risk for the development

of late-onset Alzheimer’s disease (AD) than any other gene (58, 59). While E4 is a strong
contributor to late-onset AD risk, the effect is even greater in females (60). Female E4
carriers have an increased odds ratio for AD (61), increased incidence of AD (62), elevated
hazard ratio for conversion to mild cognitive impairment (63), increased CSF tau (64), and
reduced hippocampal volume (65), compared to male E4 carriers. To date, studies
investigating the mechanism by which Ε4 and sex increase disease risk have primarily
focused on the important associations of Ε4 with the neuropathological hallmarks of AD –
i.e. the increased amyloid load seen in Ε4 carriers (66, 67) and the APOE-dependence of
tau propagation (68, 69).
Alternatively, investigating Ε4 carriers who have not yet developed neuropathology
may provide insight into early E4 mechanisms and unveil additional risk factors for AD.
For example, an early and consistent biological hallmark of AD is cerebral glucose
hypometabolism as observed by

18F-fluorodeoxyglucose

positron emission tomography

(FDG-PET) imaging (70-72). Interestingly, Ε4 carriers also display an AD-like pattern of
decreased glucose metabolism by FDG-PET long before clinical symptomology (3, 73).
Since glucose hypometabolism occurs early in AD and early in Ε4 carriers, it may represent
a critical initial phase of AD pathogenesis that predisposes individuals to subsequent
symptomology. Beyond this FDG-PET finding, it is not clear if APOE has other
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discernable metabolic effects in pre-cognitively impaired young people. Studying APOE’s
association with glucose metabolism in Ε4 carriers decades prior to disease onset may be
beneficial in designing early interventions for the metabolic derangements of AD.
In contrast to the robust FDG-PET literature, clinical research focused on how
APOE may regulate metabolism outside of the brain is limited (74). Most studies have
utilized a targeted replacement mouse model of APOE in which the murine Apoe alleles
are replaced by the human orthologs (35, 75). For example, several studies have found Ε4
mice to exhibit increased susceptibility to insulin resistance, and one report characterized
E4 mice as deficient in extracting energy from dietary sources (49, 51, 54). While these
preclinical studies have been critical to our understanding of Ε4-associated impairments in
glucose metabolism, the extent to which systemic glucose metabolism is regulated by
APOE in young healthy humans is largely unknown.
Energy expenditure (EE) is defined as the energetic cost of processes essential for
life. Indirect calorimetry (IC) assesses EE by measuring metabolic gases to calculate the
energy released when substrates are oxidized, and is the gold standard in the clinical setting
to assess nutritional status and dietary needs (76). The Weir equation (EE = 3.9 * VO2 +
1.11 VCO2) estimates EE with the assumption that anaerobic respiration is negligible and
substrates are fully oxidized to CO2 (77). This assumption is confounded when energy is
derived through non-oxidative processes such as aerobic glycolysis - when glucose is
metabolized to the non-oxidative metabolite lactate rather than pyruvate despite normoxia
(78). Increased flux through glycolysis also decreases EE since only 2 ATP are produced
via glycolytic substrate level phosphorylation in contrast to the 34 ATP from oxidative
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phosphorylation. Therefore, individuals who undergo extensive aerobic glycolysis show a
low EE due to less oxygen consumption and less ATP turnover.
Here, we use IC to study APOE genotype-dependent metabolic phenotypes in
healthy, cognitively normal young and middle-aged individuals. We observe that young
E4 carriers expend significantly less energy at rest and exhibit greater utilization of the
aerobic glycolysis pathway, as evidenced by elevated lactate abundance in the plasma
metabolome. Additionally, Ε4 carriers and Ε4 mice displayed an inability to increase
oxygen consumption after a high carbohydrate challenge – a sign of oxidative impairment
consistent with aerobic glycolysis (79). In vitro studies in astrocytes indicate that these
energy detriments are a result of increased glycolytic flux, thereby increasing lactate
production at the expense of oxidative metabolism. Together, these findings point to a role
for APOE as a critical regulator of systemic glucose metabolism.

2.2

Methods
2.2.1

Study Design

The study objectives were to i) determine if APOE genotype influences peripheral
and cerebral metabolism in young cognitively normal human subjects, and if so, ii)
elucidate potential mechanisms using mouse and cell models of human APOE. For the
clinical research study, healthy volunteers between 18-65 were prescreened for diagnoses
that may affect cognitive function (ex. stroke, Parkinson’s), metabolic diseases (diabetes),
alcoholism, drug abuse, chronic major psychiatric disorders, medications that interfere
with cognition (narcotic analgesics, anti-depressants), medications that interfere with EE
(stimulants, beta-blockers) and vision or hearing deficits that may interfere with testing.
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The prescreening checklist with a full list of medications and conditions excluded for can
be found in the supplemental materials. Eligible candidates were brought in for informed
consent after a 12-hour fast in which subjects were asked not to exercise and to abstain
from everything except for water. We employed a power analysis based on a feasibility
study, and the required sample size per group for a power level of 0.9 was calculated to be
n = 30 per “group” (i.e. E2+, E3/E3 and E4+), for a total of 90 subjects. To account for
potential biological outliers, non-consenting subjects, and post-recruitment exclusion
criteria being met, we recruited a total of 100 individuals for this observational study. Six
individuals who had IC values more than 2 standard deviations from the mean were
excluded from analysis leaving 94 individuals for analysis. As we were primarily interested
in APOE effects in young individuals, we stratified our sample population into a young
cohort (under 40 years old) and a middle-aged cohort (40-65 years old). We chose 40 as
the age-cutoff based on a meta-analysis of APOE genotype and AD-risk which found the
Ε4 effect on disease to be observable in individuals 40 and over (61). Data acquisition was
blinded as APOE genotypes were determined after the study.

2.2.2

Human study

Body mass index (BMI), waist to hip ratio, and blood pressure were first recorded.
Thereafter, participants were fitted with an airtight mask that was connected to an MGC
Diagnostics Ultima CPX metabolic cart which measures VO2, VCO2, and respiratory rate.
EE is defined as the amount of energy an individual uses to maintain homeostasis in kcal
per day, and can be calculated using the Weir equation (EE = 1.44 (3.94 VO2 + 1.11 VCO2)
(77). EE is composed of the resting energy expenditure (REE), the thermic effect of feeding
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(TEF), and activity related energy expenditure (AEE). In motionless and fasted humans,
EE is equivalent to the REE since the TEF and AEE have been controlled for. Participants
were instructed to remain motionless and to refrain from sleep for 30 minutes as data was
gathered. All testing occurred between 8:30-11:30 am in a temperature controlled (20–22
°C) out-patient research unit (Center for Clinical and Translational Science, University of
Kentucky). Body temperature was taken periodically via temporal thermometer to ensure
thermostasis and provide intermittent stimulation to ensure wakefulness. After the resting
period came a 30 minute cognitive test period. We then introduced a novel-image-novellocation (NINL) object recognition test consisting of a series of images which participants
were later asked to recall. This test has been shown previously to study APOE allele effects
on cognition (80). After the cognitive test period, a blood draw was taken via venipuncture
and placed on ice. Participants then consumed a sugary milk drink consisting of 50g of
sugar dissolved in whole milk. The drink was consumed within a two minute time span.
The mask was then refitted and participants were instructed to again remain motionless for
30 minutes for data collection. Data from the first 5 minutes of the study time periods were
excluded to allow a five minute steady state adjustment (81, 82). After the glucose
challenge, participants provided a second blood sample (~45 minutes after the initial blood
draw). Participants then exited the study and were compensated for their participation. This
study was approved by the University of Kentucky Institutional Review Board (#48365)
and was listed as Clinical Trial #NCT03109661.
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2.2.3

Genotyping

APOE genotype was determined by extracting genomic DNA from participants’
blood samples using a GenElute Blood Genomic DNA Kit (Sigma). After confirming
concentration and quality by Nanodrop, APOE genotype was determined using PCR with
TaqMan assay primers for the two allele-determining SNPs of APOE: rs7412 and rs429358
(Thermo). Positive controls for the six possible APOE genotypes were included with each
assay.

2.2.4

Plasma metabolomics

Plasma was separated from blood by centrifugation at 2500 x g for 10 minutes at
4°C, and stored in 200uL aliquots at -80°C until further use. Upon thawing, ice cold 100%
methanol solution containing 40nM L-norvaline (internal standard) was added to 80 ul of
plasma and kept on ice for 20 minutes with regular vortexing. The solution was then
centrifuged for 10 minutes (14,000 rpm, 4°C). Supernatant containing polar metabolites
was removed to a new tube and kept at -80°C until prepped for GCMS analysis (additional
details in Supplemental Methods).

2.2.5

Mice

Mice expressing human APOE display many of the phenotypic characteristics
observed in humans including several metabolic variations noted in epidemiological
studies (83-85). In this “knock-in” model, the mouse Apoe locus is targeted and replaced
with the various human APOE alleles, thereby remaining under control of the endogenous
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mouse Apoe promoter and resulting in a physiologically relevant pattern and level of
human APOE expression (3, 36, 86-89). Mice used in this study were homozygous for
either the human E3 or E4 alleles, aged 2-4 months (young) and housed in sterile microisolator cages (Lab Products, Maywood, NJ), and fed autoclaved food and acidified water
ad libitum. Animal protocols were reviewed and approved by the University of Kentucky
Institutional Animal Use and Care Committee.

2.2.6

Metabolic phenotyping

Human E3 and Ε4 mice were evaluated by indirect calorimetry (TSE Systems,
Chesterfield, MO). Mouse body composition was measured using EchoMRI (Echo
Medical Systems, Houston, TX) the morning prior to being singly housed in the indirect
calorimetry system. Mice were acclimated to singly housed cage conditions for one week
prior to beginning data recording. After five days on standard chow diet (Teklad Global
18% protein rodent diet; 2018; Teklad, Madison, WI), mice were fasted overnight before
being introduced to a high carb diet (Open Source Diets, Control Diet for Ketogenic Diet
with Mostly Cocoa Butter, D10070802) for five days. Mice were monitored for O 2
consumption, CO2 production, movement, and food and water consumption. Chambers
were sampled in succession and were reported as the average of 30 minute intervals in
reference to an unoccupied chamber. To negate the effects of activity on EE readouts, we
chose to only analyze the light cycles of the mice where activity, and feeding, is minimal.
The EE then becomes analogous to a “resting” EE similar to the resting period in the human
study and differences observed are likely due to basal metabolic rate differences instead of
confounding factors such as feeding and activity (90).
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2.2.7

Cell culture

Primary astrocytes were isolated from postnatal day 0-4 pups of mice homozygous
for E3 or Ε4. The brain was surgically excised and meninges were removed from cortical
tissue in cold DMEM. Tissue from pups of the same genotype was pooled and coarsely
chopped to encourage suspension. Tissue homogenates were incubated in serum free
DMEM with 0.25% trypsin and DNAse for 30 min with gentle shaking. Cell suspension
was then filtered through 40 µm strainer and spun for 5 min at 1100 x g. Suspended primary
cells were then plated in a poly-lysine coated plate and allowed to grow to confluency in
Advanced DMEM (Gibco) with 10% FBS. Immortalized astrocytes were derived from
targeted replacement mice expressing human APOE alleles (kind gift from Dr. David
Holtzman). These immortalized cell lines secrete human ApoE in HDL-like particles at
equivalent levels to primary astrocytes from targeted replacement APOE knock-in mice
and have been relied upon for studies of APOE’s role in astrocyte metabolism by several
groups (91-93). Cells were maintained in Advanced DMEM (Gibco) supplemented with
1mM sodium pyruvate, 1X Geneticin, and 10% fetal bovine serum unless otherwise noted.

2.2.8

Statistical analysis

All results are reported as mean +/- SEM unless otherwise stated. For comparisons
between two groups, an unpaired two-tailed Student’s t-test was used. For pair-wise
comparison of two time points a paired two-tailed Student’s t-test was used. One-way
analysis of variance (ANOVA) was used for comparing multiple groups followed by
Sidak’s multiple comparisons test. Two-way ANOVA with repeated measures was used
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for time course analysis. Pearson r correlation test was used for correlative analysis. For
dependent variables with categorical independent variables we analyzed covariance
(ANCOVA) to assess collinearity. P<0.05 was considered significant.

2.3

Results
2.3.1

Young female Ε4 carriers have a lower resting energy expenditure

We first used IC to test the effect of APOE on whole body metabolism in a cohort
of healthy volunteers (Tables 2.1 and 2.2). Using a mobile metabolic cart designed to
measure VO2 and VCO2, we assessed volunteers at rest, during a cognitive task, and after
a glucose challenge (Fig 2.1A, Fig S1). Blood samples were collected before and after the
glucose challenge to determine APOE genotype and to quantify metabolite abundance by
mass spectrometry (Fig 2.1B, Table S1).
We began each session by assessing the resting energy expenditure (REE) and
respiratory exchange ratio (RER) of participants. After a five-minute buffer to achieve
steady state (81, 82), we recorded REE over a 25 minute period at 15 second intervals and
averaged the RER and REE for each individual. There was no APOE effect on RER (Fig
S2). Consistent with previous studies, we found REE and age to be negatively correlated
(Fig 2.1C). However, when we stratified our analysis by E4 status, linear regression
revealed significantly different slopes between Ε4 carriers and non-carriers. While Ε4 noncarriers fit the overall correlation of age and REE, E4+ individuals did not fit this model
and showed no deviation from the zero slope (Fig 2.1D), suggesting an Ε4-associated
confound in the age versus energy expenditure relationship.
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To determine if the E4 effect on REE was age dependent, we separated Ε4+ and
Ε4- individuals into young (<40 years of age) and middle aged (40-65 years of age) cohorts
based on previous literature (3, 61). To account for known influences on energy
expenditure, we performed one-way analysis of covariance (ANCOVA) using average
REE values as the dependent variable, E4 status as the independent variable, and age, sex,
lean body mass (LBM), and body mass index (BMI) as covariates. After adjusting for the
covariates, we observed a significantly lower REE in female Ε4 carriers compared to noncarriers, particularly in the young cohort (Fig 2.1E). This E4 effect on REE was not
significant in males (Fig S3A-B). Together, these data suggest that there is no age-related
REE decline in E4 carriers, and that the REE-APOE interaction is modified by sex, with
female Ε4 carriers displaying lower REE.

2.3.2

Ε4 does not alter cognitive energy expenditure

We next tested if a cognitive intervention would reveal further APOE genotypespecific differences in EE. To avoid potential confounding readouts of movement, subjects
were asked to remain perfectly still while completing a challenging Novel Image Novel
Location test (Fig S1C). We observed a significant increase in average EE during the
cognitive challenge in all subjects, regardless of age or APOE status (Fig 2.1F). To assess
cognitive energy expenditure (CEE), we determined the max EE during the cognitive test
period and subtracted the average REE for each subject. We found no difference in CEE,
nor in test response accuracy, between Ε4 carriers and non-carriers (Fig 2.1G, Fig S4).
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2.3.3

Female Ε4 carriers have a lower thermic effect of feeding and fail to increase VO2
after a glucose drink
We next sought to measure the thermic effect of feeding (TEF) - a constituent of

EE that indicates the energy used to absorb, digest, and metabolize dietary energy (94, 95).
To induce TEF, all participants consumed a high carbohydrate drink in less than two
minutes (Fig S1D). Energy expenditure during the dietary challenge increased significantly
in all participants (Fig 2.1H). To account for covariates during the glucose period, we
performed two-way ANCOVA using time and IC values as dependent variables, E4 status
as the independent variable, and age, sex, LBM, and BMI as covariates. TEF was calculated
by subtracting the average REE from the maximum of EE after the glucose challenge for
each subject. Similar to resting EE, female E4 carriers displayed a significantly lower TEF
than non-carriers, particularly in the young cohort (Fig 2.1I).
We next sought to understand if there were APOE-dependent alterations in VCO2
and VO2 in the response to the glucose challenge. Plotting the time course of EE after
participants consumed the glucose drink revealed a dramatically blunted EE response in
E4+ subjects (Fig 2.2A). Further stratification by individual genotypes showed a clear
stepwise effect of APOE (Fig 2.2B). Plotting the VCO2 values revealed a similar, but nonsignificant trend of lower CO2 production in E4 carriers (Fig 2.2C-D). Analyzing the rate
of change in VO2, we observed that while non-carriers significantly increased their oxygen
consumption following the glucose drink, Ε4 carriers did not, as noted by a non-significant
slope deviation from zero (Fig 2.2E). Additionally, the AUC of VO2 showed significant
differences by E4 carrier status and individual genotypes (Fig 2.2F).
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We found the E4 effect on EE and VO2 to be significant and independent of age,
BMI, and LBM. Interestingly, when we stratified by sex we observed that the covariateadjusted E4 effect on EE and VO2 was significant in females but not in males, again
suggesting a sex-specific phenomenon (Fig S5). As EE is calculated based on VCO2 and
VO2 values, these results likely reflect decreased oxidation of the glucose drink in female
E4 carriers.

2.3.4

Targeted metabolomics reveals glycolysis as a differentially regulated pathway in
Ε4+ plasma
To determine if the observed APOE differences in energy expenditure were

reflected in the plasma metabolome, we conducted a targeted metabolomics analysis of
human plasma samples before and after the glucose challenge (Table S1). A pathway
analysis of the plasma metabolome before the glucose drink highlighted E4-associated
differences in glycolysis and pyruvate metabolism (Fig 2.3A). Further analyses of
individual metabolites revealed lactate as the metabolite most strongly affected by E4
carriage (Fig 2.3B). Indeed, E4 carriers displayed dramatically higher plasma lactate
concentrations before and after the glucose drink (Fig 2.3C; Fig S6). Following the glucose
challenge, there was an increase in the number of carbohydrate processing pathways and
metabolites that were differentially altered in Ε4 carriers (Fig 2.3D-E). A pathway
enrichment analysis highlighted multiple E4-associated changes, with top hits including
“Warburg effect” and “Transfer of acetyl groups into mitochondria” (Fig 2.3F). Together,
analysis of the plasma metabolome from cognitively normal young and middle-aged Ε4+
individuals suggests a preference for aerobic glycolysis compared to non-carriers.
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2.3.5

Ε4 mice fail to increase energy expenditure on a high carbohydrate diet

We next asked if the metabolic effects of APOE on EE would translate to a
humanized mouse model of APOE. Since mouse IC cages allow for a prolonged and
controlled assessment of metabolism, we provided a long-term glucose challenge by way
of a high carbohydrate diet (HCD). Similar to the decreases observed in E4 humans, young
mice carrying the human E4 allele exhibited significantly lower EE, VCO2, and VO2
compared to young E3 mice during their inactive period (light cycle) (Fig 2.4A). Following
introduction of a HCD, these decreases were exaggerated; Ε4 mice again showed
substantially lower EE, VCO2, and VO2 compared to E3 mice (Fig 2.4B).
We next analyzed the HCD-induced change in EE, VCO2, and VO2 from baseline
(normal chow). We found both genotypes to show significant positive changes except for
E4 VO2 (Fig 2.4C), suggesting that E4 mice fail to increase oxygen consumption in
response to excess dietary carbohydrates. These changes occurred independently of
differences in activity and food intake, as there was minimal activity or feeding during the
light cycle (the period used for analysis) in both groups (Fig S7A-B). Further, ANCOVA
revealed dissimilar correlations between body weight and EE between genotypes
indicating the variability in EE cannot be explained by body weight (Fig S7C). These data
suggest that Ε4 acts in young mice to lower EE via a mechanism outside of the typical
contributions of feeding, body mass, and activity.
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2.3.6

Stable isotope resolved metabolomics (SIRM) reveals increased lactate synthesis
and decreased entry into the TCA cycle in Ε4 brains and astrocytes
Given the decreased VO2 observed in E4 mice and humans and increased plasma

lactate concentrations in Ε4+ subjects, we hypothesized that these individuals were
diverting a higher fraction of glucose to aerobic glycolysis as opposed to oxidative
phosphorylation. To test this, we employed

13C

tracer metabolomics to quantitatively

assess glucose utilization in mice and primary astrocytes expressing human APOE (Fig
2.5A). Fasted E3 and Ε4 mice were administered an oral gavage of fully labeled [U-13C]
glucose and brain tissue was collected 45 minutes later for mass spectrometry analysis of
13C

enrichment in central carbon metabolites. The brains of Ε4 mice showed significantly

higher

13C-lactate

(fully labeled, m+3) compared to E3 mice (Fig 2.5B). Additionally,

enzyme activity measures of pyruvate dehydrogenase (PDH) – the primary entry point for
pyruvate into the TCA cycle via acetyl-CoA – showed a trend toward lower activity in Ε4
compared to E3 brain tissue, while lactate dehydrogenase (LDH) – the enzyme responsible
for interconversion of pyruvate and lactate – showed a trend toward higher activity (Fig
2.5C).
As astrocytes are the primary source of both cerebral lactate (96) and ApoE (89),
we next utilized SIRM to measure glucose utilization in vitro in primary astrocytes
expressing human APOE. E4 astrocytes showed a significant increase in both LDH activity
and in 13C-glucose conversion to lactate (Fig 2.5D-E), and as expected, lactate generation
was higher in this glycolytic cell type compared to whole brain homogenates (Fig 2.5B).
Conversely, E4 astrocytes displayed substantially lower

13C

enrichment of TCA

intermediates, suggesting decreased glucose entry into the TCA cycle (Fig 2.5F). To
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confirm these results, we performed an independent

13C-glucose

tracing experiment in

immortalized astrocytes expressing human E3 or Ε4 (97) and quantified

13C-lactate

production using nuclear magnetic resonance spectroscopy (Fig 2.5G-H). Again, Ε4
astrocytes showed significantly higher lactate synthesis, as evidenced by increased

13C-

lactate both intracellularly and in the media (Fig 2.5I). Together, these data describe an Ε4associated increase in glucose flux into late glycolysis at the expense of entry into the TCA
cycle for oxidative phosphorylation.

2.3.7

Ε4 astrocytes exhibit impairments in glucose oxidation

To functionally assess glycolytic flux in vitro, we measured the extracellular
acidification rate (ECAR, a marker of glycolysis and lactate export) before and after
glucose injection (Fig 2.6A). E4 astrocytes displayed significantly higher ECAR after
addition of glucose compared to E3 astrocytes, suggesting these cells shunt more glucose
to lactate (Fig 2.6A). Furthermore, Ε4 astrocytes showed a higher glycolytic capacity, as
shown by a heightened ECAR response to oligomycin - an inhibitor of mitochondrial
respiration (Fig 2.6B). We then measured glucose oxidation by assessing the oxygen
consumption rate (OCR). Ε4 astrocytes displayed significantly lower OCR both before and
after addition of glucose to the media, suggesting an inherent reduction in oxidative
metabolism in Ε4 astrocytes relative to E3 (Fig 2.6C-D). Together these results further
confirm an E4-associated shift toward glycolysis (Fig 2.6E).
We next measured glucose oxidation by treating astrocytes with radiolabeled 14Cglucose and capturing the oxidative product 14CO2. Ε4 astrocytes oxidized less glucose to
CO2 compared to E3, but only when the radiolabel ([nM]) was given with a substantial
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amount of non-labeled glucose ([mM]) (Fig 2.6F). Ε4 astrocytes also displayed decreased
capacity and flexibility in regards to glucose oxidation, as they were relatively unable to
increase glucose oxidation when other fuel sources (fatty acids and glutamine) were
inhibited (Fig 2.6G). We reasoned that lower rates of glucose oxidation in a glucose rich
environment in E4 cells may be due to increased conversion of glucose to lactate, which in
turn inhibits downstream oxidative processes (98). Therefore, we tested glucose oxidation
following lactate supplementation, and found that Ε4 astrocytes oxidize less glucose in the
presence of lactate than E3 astrocytes (Fig 2.6H). Together, these results suggest that Ε4
astrocytes exhibit increased reliance on aerobic glycolysis and are less flexible and less
able to oxidize glucose, a phenotype seemingly exacerbated by a high glucose environment
or the presence of lactate.

2.4

Discussion

In the current study, we used indirect calorimetry to show that APOE4 reduces
energy expenditure in a cohort of young cognitively normal females, a phenomenon
exacerbated by a dietary glucose challenge. Analysis of the plasma metabolome revealed
E4-associated increases in pathways related to carbohydrate processing, specifically
aerobic glycolysis, highlighted by higher concentrations of the glycolytic end-product
lactate. By applying stable isotope-resolved metabolomics in vivo and functional assays of
cellular respiration in vitro, we discovered that both E4 expressing mouse brains and E4
expressing astrocytes increase glucose flux through aerobic glycolysis at the expense of
TCA cycle entry and oxidative phosphorylation. Cumulatively, these data highlight a
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novel mechanism whereby Ε4 lowers energy expenditure in young women and decreases
glucose oxidation by redirecting flux through aerobic glycolysis.
Detecting early symptoms of eventual cognitive decline is important for primary
prevention of AD (99). Drugs advanced as potential AD therapeutics have targeted
pathways associated with neuropathology, such as tau anti-sense oligonucleotides and
amyloid-directed monoclonal antibodies (100). Given the largely disappointing trial
outcomes, these therapies may be intervening after a ‘point of no return’ and thus offer
minimal benefit in prognosis (101). In order to design therapies for early interventions in
those at risk for AD, we must first identify measurable biomarkers whose severity and/or
change over time correlate with risk for clinically observable AD. One such early
biomarker of eventual AD onset is low cerebral metabolic rates for glucose (CMRglc).
APOE, the strongest genetic risk factor for late-onset AD, is now recognized as a
strong modulator of cerebral metabolism, with Ε4+ individuals demonstrating metabolic
alterations congruent with AD patients (4). Even cognitively normal Ε4 carriers
demonstrate this pattern of glucose hypometabolism, thereby lending support to decreased
CMRglc being an inherent biological feature of Ε4, rather than simply a byproduct of
dementia (102-104). Importantly, these metabolic deficits are present decades in advance
of AD onset in Ε4+ individuals, evidenced by reductions in CMRglc observed as early as
their 20s (3). While lower CMRglc is measurable in young Ε4 carriers, a need exists for
identification of other measurable metabolic alterations associated with APOE and glucose
metabolism. Impairments in systemic metabolism are also strongly inversely correlated
with CMRglc (105), suggesting that peripheral and brain metabolism are tightly coupled.
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Thus, we hypothesized that whole body energy expenditure (EE) may be a measurable
metabolic biomarker of young Ε4 carriers.
We used IC to assess EE in young and middle-aged volunteers with and without
the Ε4 allele to test for potential prodromal effects of APOE on metabolism. While using
IC for metabolic studies is common in clinical settings and exercise studies (106, 107), to
our knowledge the method has not been previously applied to investigate biomarkers of
cognitive impairment. Thus, repurposing IC to study the metabolic effects of an AD risk
factor such as Ε4 represents a mobile, simple, and cost-effective new approach. To our
knowledge, only two other studies have attempted to utilize IC to quantify the contribution
of cerebral activation (i.e. a mental task) to whole body metabolic measures (108, 109).
While we did not observe an APOE effect on IC measures during the cognitive challenge,
we did find that IC is a sensitive tool to evaluate metabolic changes due to mental stress,
as all participants showed a significant increase in EE. These results support claims that
the brain consumes ~20% of EE despite only accounting for ~2% of body mass (110).
Although resting EE was significantly lower in E4 carriers at rest, the most striking
effect of APOE was observed after participants underwent a dietary carbohydrate
challenge. There, E4+ individuals failed to increase VO2, leading to a significantly lower
EE compared to non-carriers. In order to study the effect of a long-term high carbohydrate
challenge, as well as test the utility of a human APOE mouse model, we fed E3 and E4
mice a high carbohydrate diet (HCD). An E4-associated decrease in EE observed on a
normal chow was exacerbated over the course of the HCD. Previous studies have shown
differences in substrate utilization in these mouse models of human APOE (54, 111), and
our findings now suggest that a HCD exaggerates E4 differences in EE.
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Current understanding supports a triad of primary risk factors for the development
of late-onset AD: old-age, E4, and female sex. Female study participants that were E4
carriers showed significant decreases in energy expenditure at rest and after the glucose
challenge. Studies have shown that females are at a greater risk for developing AD, as 60%
of AD patients are female (60, 112). Female E4 carriers are also more likely to develop
AD than male E4 carriers (63) and show increased neuropathology (113). Sex specific E4
effects have also been observed in healthy older adults - female E4 carriers displayed
greater CSF tau levels than female E4 non-carriers, a finding not observed in males (114).
Here, we observed metabolic signatures in female E4 carriers that were different from
female non-carriers decades prior to cognitive impairment, supporting a synergism of E4
and female sex which increases AD risk.
Aerobic glycolysis refers to the metabolism of glucose to lactate instead of the
oxidative TCA cycle, despite the presence of abundant oxygen. This paradoxical
phenomenon occurs in young individuals with a peak around five years of age, when 30%
of the brain’s glucose is processed anaerobically and then steadily declines with age (115).
Aerobic glycolysis in the brain appears to be cell and region specific, with astrocytes
playing a major role in certain regions such as the dorsolateral prefrontal cortex, precuneus,
and the posterior cingulate cortex (116). Importantly, areas associated with aerobic
glycolysis also overlap with areas known to accumulate amyloid β, indicating that the
anaerobic metabolism of certain brain regions may possibly predict amyloid burden in later
life (117). Furthermore, a recent large-scale proteomics study implicated proteins involved
in glial sugar metabolism as most significantly associated with AD pathology and cognitive
impairment (118), while another showed rates of aerobic glycolysis in preclinical AD
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predict higher tau deposition (119). Here, we observed that Ε4 carriers exhibit a
bioenergetic profile consistent with an active aerobic glycolysis phenotype. When we
performed metabolic pathway and enrichment analyses on plasma metabolites extracted
from Ε4 carriers and non-carriers, the most significant pathways altered were “glycolysis”
and “Warburg effect”, respectively, while the most significantly increased metabolite in
E4 subjects was lactate. Together, these changes in the plasma metabolome of young and
middle aged E4 carriers point to a role for APOE in regulating aerobic glycolysis.
Using metabolic assays and stable isotope-resolved metabolomics in vivo and in
vitro, we identified an Ε4-associated bioenergetic phenotype of impaired glucose oxidation
and increased glycolysis which promotes lactate production. These results are congruent
with other Ε4 and AD studies. For example, a recent study demonstrated that Ε4 astrocytes
have increased lactate production (120), and neurons expressing Ε4 exhibit increased
reliance on glycolysis for ATP production with apparent deficits in mitochondrial
respiration (121). Fibroblasts from AD patients also show a Warburg-type shift from
oxidative phosphorylation to glycolysis with increased lactate production (122). The
potential mechanism underlying how AD and/or Ε4 alters metabolic efficiency to induce
these effects is unclear. It has been proposed that Ε4 directly causes mitochondrial
dysfunction, which is a known metabolic derangement of AD (123). Ε4 has been shown to
reduce mitochondrial membrane potential by directly binding to complexes involved in
oxidative phosphorylation and decreasing their activity (124). Treating naïve fibroblasts
with astrocyte conditioned media from the same immortalized E3 and Ε4-expressing
astrocytes we used here induced a decrease in OCR in tandem with an increase in lipid
synthesis and lipid droplet formation (125). We have also observed this increased lipid
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droplet formation in Ε4 astrocytes (126), as have others (127). A seminal study on lipid
droplets in the brain found that lipid droplet accumulation in glia is APOE-dependent and
directly linked to neurodegeneration and lactate transport (128). The intriguing link
between increased lactate and increased lipid droplets in Ε4 glia remains to be fully
elucidated.
Interestingly, recent evidence has shown that lactate is an energy substrate used by
the brain (129) and a competitive glucose alternative (130-132). Lactate has also been
shown to decrease FDG-PET signal (133). An increase in astrocyte-derived lactate in Ε4
carriers may compete with glucose as a substrate for brain metabolism and decrease
CMRglc. Further, an increase in aerobic glycolysis might also act to lower energy
expenditure, as glycolysis produces only 2 moles of ATP compared to the 34 moles of ATP
from a mole of glucose metabolized via mitochondrial oxidative phosphorylation. This
balance of anaerobic glycolysis versus oxidative phosphorylation behaves reciprocally
(134). Increased mitochondrial ATP production downregulates glycolysis, while glycolytic
ATP synthesis can suppress aerobic respiration (135). Given our findings of lower O2
consumption and increased production of lactate, we speculate that E4 carriers have lower
EE due to glycolysis being less energetically costly than downstream pathways.
Our study has several limitations. As a primary goal was to assess individual
metabolic responses to glucose, we performed blood draws immediately prior and
immediately after the glucose challenge. It may be possible that mental stress during the
cognitive challenge (which occurred prior to the first blood draw) altered the plasma
metabolome beyond the normal resting state. We did however provide time after
completion of the cognitive test for a “post-cog” rest in which participants were asked to
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relax and breathe normally, similar to the initial rest period. Another potential confounder
is that we provided glucose in the form of a sugary milk drink for the glucose challenge.
While we used 50g of sugar based on clinical guidelines for glucose challenges (136), milk
also includes fats and proteins. However, the high relative content of carbohydrates to other
macronutrients ensures that any observed response (particularly at the ~30 minute time
point analyzed) can be primarily attributed to carbohydrate metabolism. Indeed, the
pathways most altered by the glucose challenge included galactose metabolism, starch and
sucrose metabolism, and glycolysis. Finally, while we found E2 to be associated with lower
plasma lactate and higher EE relative to non-E2 carriers, the study did not include any
homozygous E2 carriers and the low overall allele frequency makes interpretation
challenging. Still, these results are intriguing based on E2 being a known protective allele
for AD (59, 61), and further study of energy expenditure and glucose metabolism in E2
carriers is warranted.
Using primary astrocytes, humanized mouse models, and cognitively unimpaired
humans, we demonstrate decreased energy expenditure in young E4+ individuals. This
phenomenon was sex-specific, exaggerated following a dietary glucose challenge, and
reflected in a decreased rate of glucose oxidation in preference for aerobic glycolysis.
While many questions remain, our study highlights novel roles for APOE and sex in
modulating systemic glucose metabolism and provides a feasible method to assess APOEdependent metabolic signatures in pre-symptomatic young individuals. These findings
provide important insights that may help to define dietary and pharmacological approaches
to delay or prevent incipient AD in high-risk E4+ individuals.
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Figure 2.1 Female Ε4 carriers show lower resting energy expenditure and lower thermic
effect of feeding after a glucose challenge.
(A) Experimental design of study. Individual components of energy expenditure were
assessed in three distinct periods. Resting energy expenditure (REE) was assessed during
the resting period. Cognitive energy expenditure (CEE) was assessed during the cognitive
challenge and defined as difference in the area under the curve (AUC) of energy
expenditure (EE) during the cognitive challenge and the AUC of EE from the resting period.
Thermic effect of feeding (TEF) was assessed during the glucose challenge and calculated
as the difference in AUC of EE during the glucose challenge and AUC of REE. (B) APOE
genotypes of subjects represented in the study (E4- n=61, E4+ n=33; E2/E4 n=2, E2/E3
n=10, E3/E3 n=51, E3/E4 n=28, E4/E4 n=3). (C) Correlation of average REE with
participant age (Pearson correlation R2=0.11, **P<0.01, n=94). (D) Correlation of average
REE and participant age separated by Ε4 carriers (purple) and non-carriers (blue) (Ε4R2=0.233, ****P<0.0001; Ε4+ R2 =0.0042, P=0.719, E4- n=61 and E4+ n=33). Shaded
areas refer to 95% confidence intervals. (E) Average REE for all, young, and middle-age
E4- (n=44, 33, and 11 respectively) and E4+ females (n=27, 20, and 7 respectively)
(*P<0.05, **P<0.01, unpaired t-test, two-tailed). (F) Average EE between resting and
cognitive test periods in young (n=71) and middle-aged (n=23) participants. (***P<0.001,
paired t-test, two-tailed). (G) CEE for all female participants and for the two age cohorts.
(H) Average EE between resting and glucose challenge periods in young and middle-aged
participants (***P<0.001, paired t-test, two-tailed). (I) TEF for all females and for the two
age cohorts, further separated by Ε4 carriers and non-carriers. (*P<0.05, unpaired t-test,
two-tailed).
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Figure 2.2 Female Ε4 carriers show lower energy expenditure and lower oxygen
consumption after a glucose drink.
(A) Energy expenditure (EE) of female Ε4 carriers (purple) and Ε4 non-carriers (blue)
during the glucose challenge. Values shown are means (lines) +/- SEM (shaded). (E4n=44, E4+ n=27; *P<0.05, Two-way ANOVA repeated measures) (B) Incremental area
under the curve (AUC) of EE was determined by Ε4 carriage and further by respective
APOE genotypes in all participants. (E4- n=61, E4+ n=33; E2/E4 n=2, E2/E3 n=10, E3/E3
n=51, E3/E4 n=28, E4/E4 n=3; **P<0.01, unpaired t-test, two-tailed; #P<0.05 One-way
ANOVA,) (C) Time course of average VCO2 values of Ε4- and Ε4+ females during the
glucose challenge period. Dashed lines refer to linear regression result. (D) AUC of VCO2
for all participants. (E) Time course of average female VO2 during glucose challenge.
(*P<0.05, Two-way ANOVA repeated measures) (F) AUC of VO2 for all participants
(*P<0.05, unpaired t-test, two-tailed; #P<0.05 One-way ANOVA)
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Figure 2.3 Targeted metabolomics reveals lactate as a differentially regulated metabolite
in E4+ plasma.
(A,D) Pathway impact analysis highlights pyruvate metabolism and glycolysis as pathways
significantly altered by E4 carriage in human plasma at baseline (A), while multiple
carbohydrate and lipid processing pathways are altered by E4 carriage following the
glucose drink (D) (FDR <0.01). (B,E) Volcano plots showing changes in plasma
metabolites. Lactate was the most significantly altered metabolite by APOE genotype at
baseline (B), while multiple metabolites differed post-glucose drink (E) (ANOVA, FDR
<0.05). (C) Lactate values in individual subjects as determined by GC-MS analysis. (F)
Enrichment analysis highlights multiple metabolic pathways as significantly altered by E4
carriage following the glucose drink, including the top hit of ‘Warburg effect’. All
comparisons are E4+ (n=33) vs E4- (n=61); A-B, denote analysis of pre-glucose drink
plasma samples; D-F, denote post-drink plasma samples.
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Figure 2.4 E4 mice show lower energy expenditure that is exacerbated by a high
carbohydrate diet.
E3 and E4 mice were housed individually for 48 hours with ad libitum access to normal
chow (A) or a high carbohydrate diet (HCD) (B). Dark cycles are indicated in grey with
light cycles in white. Light cycles were used for calculating averages of energy
expenditure, VCO2 and VO2 (shown to the right) (***P<0.0001, ****P<0.00001, unpaired
t-test, two-tailed; E3 n=13, E4 n = 20). Violin plot values represent means (black dashed
line) and upper and lower quartiles (gray dotted line).
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Figure 2.5 Stable isotope resolved metabolomics reveals increased lactate synthesis and
decreased entry into TCA cycle in E4 brains and astrocytes.
(A) Experimental design (13C, blue filled circles; 12C, white circles; (m+n, where n is the
number of 13C labeled carbons within a metabolite). (B) [U-13C] glucose was administered
in vivo to E3 (n=6) and E4 (n=8) mice via oral gavage, brain tissue was collected after 2
hours, and metabolites analyzed for 13C enrichment in pyruvate and lactate. While fully
labeled pyruvate is present in similar amounts in E3 and E4 brains, lactate synthesized from
13C-glucose is higher in E4 mouse brains (C) LDH activity is higher in E4 brains as
estimated by the ratio of lactate (m+3) / pyruvate (m+3), while glucose entry into the TCA
cycle via pyruvate dehydrogenase is decreased in E4 brains as estimated by the citrate
(m+2) / pyruvate (m+3) ratio. (D) E3 and E4 expressing astrocytes were cultured in [U13C] glucose media for 24 hours, media collected, cells washed, and metabolites analyzed
for 13C enrichment (n=6). Primary astrocytes expressing E4 show increased 13C enrichment
in lactate, (E) higher LDH activity (F) and decreased 13C enrichment in the TCA cycle
(average of all detected TCA intermediates) (G-H) Increased lactate synthesis as measured
by HSQCAD NMR spectroscopy (n=3). Representative NMR spectra (I) showing E4
astrocytes have increased intracellular 13C-lactate and export more lactate into extracellular
media.
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Figure 2.6 E4 astrocytes show increased glycolysis and lower oxidative respiration.
(A) Extracellular acidification rate (ECAR) of E3 and E4 primary astrocytes shown over
time during the glycolysis stress test (n=24 for both groups). (B) Contributions to ECAR
at baseline, in response to glucose (glycolysis), in response to stress (glycolytic capacity),
and un-tapped reserve were calculated and shown. (*P<0.05, ***P<0.001, Unpaired t-test,
two tailed) Values represent means +/- SEM. (C) Oxygen consumption rate (OCR) during
the glycolysis stress test assay was graphed over time and (D) represented as average
respiration before and after glucose (***P<0.001, ****P<0.0001, unpaired t-test, two
tailed). Values represent means +/- SEM. (E) Metabolic phenotypes of E3 and E4
astrocytes were characterized by plotting ECAR vs. OCR. (F) E3 and E4 astrocytes were
incubated in glucose free media (-) or glucose rich media (+) and oxidation of 1.0 µCi/mL
14C-glucose was measured by trapping 14CO2 and counting radio activity. (*P<0.05
unpaired t-test, two-tailed, n=4 per genotype) Values represent means of percentages of
E3. (G) Glucose oxidation capacity, dependency, and flexibility was assessed in E3 and
E4 astrocytes via the Mito Fuel Flex Assay. (*P<0.05 Two-way ANOVA, Sidak’s multiple
comparisons test) Values represent means +/- SEM. (H) E3 and E4 astrocytes were
incubated in 1.0 µCi/mL 14C-glucose with (+) or without (-) 12.5mM lactate (*P<0.05,
unpaired t-test, two-tailed, n=3 per genotype). Values represent mean of percent change
from control (no lactate) +/- SEM.
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Table 2.1 Age, sex, and APOE genotype of cognitively normal individuals according to Ε4
carriage and age cohort (young=18-39, middle-aged=40-65).
Values represent means +/- (SD).
Age
Average Age
(SD)

Sex (N)
P

Male

APOE Genotype (N)

Female

APOE
2/3

APOE
3/3

APOE
2/4

APOE
3/4

APOE
4/4

Young
Ε4 Non-carriers
(E4-)

24.91
13

33

8

38

0

0

0

5

20

0

0

2

21

2

(4.84)
0.486
25.84

Ε4 Carriers (E4+)
(6.08)

Middle-age
Ε4 Non-carriers
(E4-)

51.18
4

11

2

13

0

0

0

1

7

0

0

0

7

1

(7.79)
0.233
55.5

Ε4 Carriers (E4+)
(8.78)
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Table 2.2 Clinical characteristics of cognitively unimpaired individuals according to Ε4
carriage and age cohort (young=18-39, middle-aged=40-65).
Values represent means +/- (SD). Ca, Caucasian; AA, African American; His, Hispanic;
A, Asian; BMI, body mass index.
Race (N)

Ca

AA

His

Vitals

A

BMI
(kg/m2)

Waist/
P

P
Hip Ratio

Systolic
(mmHg)

P

Diastolic
(mmHg)

P

Lean
Body
Mass (kg)

P

Young
25.15
E4-

34

4

3

0.86

123.2

(3.83)

(0.1)

(21.2)

0.93
E4+

22

3

0

72.3

48.2

4
0.56

(14.4)
0.79

(7.3)
0.9

0.33

25.06

0.87

121.8

72.1

46.4

(4.72)

(0.1)

(18.5)

(12.1)

(7.2)

123.4

74.2

47.1

0

Middle-age
25.83
E4-

12

3

1

0.9

0
-6.07

(0.1)

(17.6)

0.45
E4+

7

0

1

0.14

(8.7)
0.76

(7.7)
0.6

0.63

27.92

0.81

126

76.8

48.9

-6.73

(0.2)

(23.1)

(15.9)

(9.2)

0
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CHAPTER 3. LIPID DROPLETS IN NEURODEGENERATIVE DISORDERS
[This chapter consists of material adapted from an accepted manuscript: Farmer BC, Walsh
AE, Kluemper JC, Johnson LA. Lipid Droplets in Neurodegenerative Disorders. Frontiers
in Neuroscience. Accepted June 23, 2020. doi: 10.3389/fnins.2020.00742.]
3.1

Introduction
Lipid droplets (LDs) are spherical organelles that store intracellular neutral lipid such

as triacylglycerols (TAGs) and cholesteryl esters (CEs) (137, 138). LDs serve as lipid
reservoirs for cells by providing substrates for membrane formation and energy metabolism
(139). Adipose tissue is the most LD-enriched tissue in the body, where fatty acids are
stored in times of nutrient excess and then mobilized with increased energy demand (140).
LDs also affect physiological processes in the periphery beyond simple fatty acid storage
and supply, such as in inflammation and insulin signaling. For example, LDs in various
immune cell types contain a large pool of intracellular arachidonic acid (AA), which
provides a reserve of precursors for eicosanoid synthesis (141-143) Enzymes involved in
AA processing have been demonstrated to LDs, indicating that these organelles serve as a
supply site for inflammation (144). Additionally, LDs have been linked to peripheral
metabolic dysfunction such as ectopic lipid accumulation (145) and insulin resistance
(146). Overexpression of LD-associated proteins such as Cidea increase fat accumulation
in mice, and human expression of LD proteins in adipose correlates with clinical insulin
resistance (147). These studies therefore suggest a role for LDs in obesity-driven metabolic
dysregulation.
Lipid droplets may also affect cellular physiology and function in the central nervous
system (CNS). The brain is the second most lipid-rich organ (148), storing 20% of the
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body’s total cholesterol (149). Alteration in the lipid composition of CNS cells has been
shown to affect cell function and normal neural activity (150, 151). Notably,
neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease
(PD), share lipid dysregulation as a metabolic feature in disease pathology. In this review,
we discuss evolving knowledge and recent advances in understanding the contribution of
LDs to pathogenesis of neurodegenerative diseases. Growing knowledge of LDs in the
central nervous system is important to the advancement of the field, as these dynamic
organelles may reveal common mechanisms and potential therapeutic targets to
neurodegenerative disease.

3.2

LD structure, composition, and biogenesis
Hydrophobic molecules such as TAGs, CEs, and retinyl esters constitute the core of

a lipid droplet (152), while the outer surface is formed by an amphipathic lipid monolayer
embedded with LD-associated proteins. (The general structure of an LD is illustrated in
Figure 3.1). Additionally, proteins can reside in the LD core depending on the cell type.
This unique monolayer distinguishes LDs from organelles of similar size, such as
lysosomes and endosomes, as the latter exhibit a lipid bilayer. Of the many LD-associated
proteins, members of the perilipin family have been well described for their essential roles
in LD metabolic regulation (153). The exterior protein components of LDs allow for a
variety of unique interactions that may explain the myriad of cellular roles accomplished
via LDs in energy homeostasis, cellular communication, and disease.
Lipid droplets arise from the endoplasmic reticulum (ER) by budding off the
cytoplasmic leaflet of the ER membrane (154). They are comprised of acyl-glycerols that
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are synthesized through the action of diacylglycerol transferases (DGATs), which convert
acyl-CoA-bound fatty acids and diacylglycerols (DAGs) into the TAGs that fill the LD
core (155). Cholesterol acyltransferases synthesize CEs which are also incorporated into
the core of nascent LDs (156). Once separated from the ER membrane, LDs may continue
to grow via LD fusion and further TAG incorporation. Fusion of LDs with the aid of
members of Cell death-inducing DFF45-like effector (CIDE) family proteins (157)
coalesce smaller LDs into larger LDs. Re-localization of TAG synthesis enzymes like
DGAT2 and GPAT4 from the ER to the LD surface allows direct synthesis of TAGs from
cellular lipid sources (158), such as fatty acids derived from autophagic phospholipid
breakdown (159). The incorporation of cellular debris into LDs is commonly seen during
periods of stress and starvation and are thought to protect the cells from lipotoxicity (160).
LDs exhibit a variety of protein and lipid signatures, and these various compositions can
help determine LD localization and utilization. For example, perilipin 2 (PLIN2) has
relatively low control over lipolysis, so LDs that contain PLIN2 may be more easily broken
down. Conversely, PLIN1 and PLIN5 actively promote lipolysis when activated. PLIN1
acts through its release of CGI-58, a co-activator of adipose triglyceride lipase (ATGL)
(161), while PLIN5 binds directly to ATGL to promote lipolysis (162). Therefore, LDs
with varying PLIN proteins will behave differently across various tissues and
environmental conditions (153).
Lipid homeostasis is necessary for maintaining neuronal function and synaptic
plasticity (163), and dynamic interaction between perilipins and lipases on the LD surface
regulate cellular lipid storage, breakdown, and metabolism (164). In most cells, the bulk of
LD breakdown is accomplished through ATGL, another LD outer layer protein (165).

45

Lipophagy is also a recognized LD breakdown process, in which an LD is taken up into an
autophagosome and subsequently fuses with a lysosome to breakdown LD contents mainly
through lipid acid lipases (166). During times of metabolic stress, lipases cleave
triglycerides into FAs, which are then processed in the mitochondria to liberate the energy
stored in droplets via beta-oxidation into acetyl-CoA and subsequent TCA cycle activity
and oxidative phosphorylation (167). LDs have been shown to provide energy substrates
(126, 168), lipid signaling molecules (169), and membrane infrastructure materials (170)
for various cell types.

3.3

LD formation in cells of the brain
Essentially all brain cell types have been shown to form LDs (Table 3.1 and Figure

3.2). A recent study claimed that the majority of brain LDs (stained with the fluorescent
neutral lipid probe BODIPY) were co-localized with ionized calcium binding adaptor
molecule 1 (Iba1), a microglia/macrophage-specific protein. This finding implicates
microglia as a main harbor of LDs (171). These lipid-associated microglia had a unique
transcriptomic signature compared to non-LD-laden microglia, suggesting that LDs in
microglia are either a cause or result of substantial transcriptional modulations. However,
subsequent co-localization using other brain cell-specific markers was not reported in this
study, leaving the door open for other cell types to be involved. For example, ependymal
cells that line the cerebral ventricular system have been shown to accumulate LDs, along
with Glial fibrillary acidic protein (GFAP) positive cells that are closely associated in the
ependymal niche (GFAP is a common marker for astrocytes and ependymal cells) (172).
Lesions to the CNS have also induced LDs in neurons and astrocytes (173), and glial cells
have been shown to form LDs from phagocytosed myelin fragments (174). Finally, a
46

thorough immunofluorescence study examining cell types that harbor PLIN positive
droplets found Iba1+, GFAP+, NeuN+ (a neuron specific antibody), and S100+ (a
calcium binding protein that is localized in astrocytes) to colocalize with droplets (175).
Together, these studies and others demonstrate that multiple cell types in the brain are
capable of forming LDs.

3.4

Anatomic structures associated with LDs in the brain
The subventricular zone (SVZ) has surfaced as a key region for lipid droplets in the

brain. The SVZ lines the wall of the lateral ventricles and is composed of neural stem cells
that are capable of differentiating into various CNS lineages (176). This highly active and
heterogeneous cellular region is an energetically needy zone, and it is reasonable to expect
ample energy stores are on board in order to meet its energetic needs (177). It was first
shown that large LDs were found in the ependyma of the SVZ (178). This was
accomplished using an electron microscopy approach that detailed the associations of
various SVZ cell types with confirmatory immunostaining.
Another group found that the LD lipase ATGL, which is encoded by the patatin-like
phospholipase domain-containing protein 2 (PNPLA2) gene, is highly active in the SVZ
and choroid plexus. Furthermore, mutating PNPLA2 led to a significant increase in LD
formation in both areas (165). This study was the first to report a function of PNPLA2 in
the brain and describe its regional role in maintaining cerebral lipid metabolism.
Additionally, knock out of the GTPase regulator associated with focal adhesion kinase-1
(GRAF1) induced LDs in the brains of post-natal day seven pups (179). Apart from studies
of LDs in the brain arising from genetic alterations, it was found that LDs accumulate in
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the SVZ progressively with age; 12-month-old mice showed a nearly two-fold increase in
LDs in the SVZ compared to 3-month-old mice (180).
The SVZ has also been shown to harbor LDs in the context of Alzheimer’s disease
(AD). Hamilton and colleagues showed that both an AD mouse model and AD human postmortem tissue accumulate LDs along the lateral ventricle (181). Using tandem mass
spectrometry, the LD contents were identified, revealing high concentrations of oleic acidenriched TAGs (181). Interestingly, direct infusion of oleic acid into the lateral ventricle
was sufficient to induce LD formation along the SVZ, but insufficient to impair
neurogenesis (181). Another group found the choroid plexus to have more LDs as AD
progressed in human post mortem tissue (182). Further studies are needed to clarify the
role of LDs in the SVZ in normal aging and neurodegeneration.
Although the SVZ is the most extensively studied brain region with regards to LD
formation, other structures such as the frontal cortex, hippocampus, olfactory bulbs, and
hypothalamus have been shown to accumulate LDs (Table 3.1). In fact, prior studies on
the hypothalamus indicate that LDs may affect certain processes such as satiety (183). In
this study, Kaushik demonstrates that autophagy during starvation leads to the mobilization
of neuronal lipids which can then increase food intake though the upregulation of agoutiregulated peptide. This is just one of many studies which explore the wide variety of brain
regions and biological processes which LDs can affect (Table 3.1).
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3.5

What causes lipid droplets to form in the brain?
3.5.1

Aging

Lipid droplets appear to accumulate in the brain during the normal process of aging.
For example, analysis of microglia from 20-month-old mice revealed an abundance of
BODIPY+ cells in comparison to a matched 3-month-old cohort (171). Analyses of human
tissue (postmortem) also revealed that PLIN2+ Iba1+ microglia were more frequent in an
aged (67-years-old) individual than in a young (22-years-old) individual (171). A
significant increase in LDs has also been observed in the pia mater, cortex, and striatum in
18-month-old mice as compared to middle aged mice (175). Furthermore, an electron
microscopy analysis of the basement membrane of the blood brain barrier (BBB) in 6month-old versus 24-month-old mice showed an age-dependent accumulation of LDs
which caused significant thickening of the basement membrane (184). On the contrary,
LDs are more commonly found in perivascular cells in middle age and then seem to shift
toward the parenchyma in old age (175). Given these findings, age appears to regulate LD
accumulation and regional deposition.

3.5.2

Inflammation

From in vitro studies of LDs to ex vivo brain imaging, inflammation has repeatedly
been associated with LD formation as both a cause and as an effect (143).
Lipopolysaccharide (LPS), a commonly employed pro-inflammatory stimulus, has been
shown to increase the number and size of LDs in microglia (185). PLIN2 was shown to
colocalize with these droplets, providing more evidence that PLIN2 is an LD-associated
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protein that can be considered a marker for both LDs and inflammation in the brain. This
was repeated recently in microglia-derived BV2 cells and expanded into an in vivo model
of LPS treatment. That study by Marschallinger and colleagues found that more microglia
contained LDs in LPS treated mice when compared to non-treated controls (171). To assess
how the vasculature might affect LDs in the brain, Lee and colleagues i.v. infused
triglyceride-rich lipoproteins (TGRL) and lipoprotein lipase into mice and found increased
BBB permeability, therefore indicating that hyperlipidemia may increase lipid spill-over
into the brain. To test how this treatment affected resident brain cells, they treated normal
human astrocytes with the TGRL lipolysis products and found increased LD formation
(186). Another study found that palmitate treatment of isolated primary astrocytes
increased inflammatory markers including TNF-alpha, IL-1 beta, IL-6, and MCP-1 in
addition to Oil Red O (a fat-soluble dye) staining and PLIN1 and PLIN2 transcription.
Interestingly, treatment of microglia with conditioned media from lipid-loaded astrocytes
enhanced microglial chemotaxis through a CCR2-MCP1 mechanism (187). These data
suggest that LD-associated astrocyte inflammation may subsequently signal to microglia
to augment the inflammatory response. However, it remains to be seen whether
inflammation causes LDs, LDs cause inflammation, or both.

3.5.3

Oxidative Stress

Intracellular reactive oxygen species (ROS), as well as ectopic treatment with
oxidative stressors such as hydrogen peroxide, induce LD formation in various cell types
in the periphery (188-190). Similarly, increased oxidative stress in the brain appears to
drive LD accumulation in a cell-specific manner. For example, neuronal hyperactivity from
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trauma or chemogenetic activation increases glial LD accumulation (173). These LD-laden
glia upregulate genes to neutralize the peroxidated lipids generated by activated neurons.
Astrocytes in particular appear to be uniquely suited for ROS management due at least in
part to fatty acid binding protein 7 expression (191). Liu and colleagues first proposed this
neuron-astrocyte metabolic coupling model in which neurons under stress export oxidized
lipids to astrocytes as a means of neuroprotection (128, 192). LDs in glia may then be
viewed as indirect indicators of neuronal damage from oxidative stress. Protective LD
formation in glia has also been observed in the SVZ niche, where glia protect neuroblasts
from peroxidation and thereby promote neural stem cell proliferation (193). Therefore,
oxidative stress appears to be a driver of LD formation in the brain both under formative
physiological processes during neuronal development, as well as in diseases associated
with increased neuronal oxidative stress.

3.6

What neurodegenerative disorders have been linked to lipid droplets?
3.6.1

Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron
disease (194). ALS is characterized by the progressive degradation of motor neurons in the
CNS, leading to the inability to both initiate and control muscle movement. In addition to
genetic mutations, altered metabolic function in ALS has been observed in cellular
processes implicated in ALS pathology such as cell stress and energy homeostasis (195).
Recent studies interested in lipid metabolism have shed light on connections
between LDs and ALS pathology (196). For example, it is known that mutations in the
human VAMP-associated protein B (hVAPB) cause ALS, although the disease-causing
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mechanism itself remains unclear (197). Sanhueza and colleagues performed a genomewide screen in Drosophila to identify pathways involved in hVAPB-induced neurotoxicity
and found that the list of modifiers was mostly enriched for proteins linked to LD dynamics.
One modifier highlighted in this study was acyl-CoA synthetase long-chain (Acsl). Acsl
promotes LD biogenesis and its downregulation reduces LD nucleation which decreases
the size and number of mature LDs (198). Furthermore, another group showed that gain of
function mutations in the LD protein seipin contributed to motor neuron disease symptoms
in mice (197, 199). Together these studies suggest that impaired LD biogenesis may be an
important pathological aspect to hVAPB-mediated ALS.
A mutation that contributes to an early onset form of ALS occurs in the gene SPG11
and affects lysosome recycling (200). Branchu and colleagues observed intracellular lipid
accumulation followed by lipid clearance from lysosomes into droplets in wild-type (WT)
mice. However, in Spg11 knockout mice, there was a significantly slower rate of lipid
clearance and a decrease in LD size and number. Another study that implicates aberrant
lysosomal function as a contributor to ALS reported that the C9orf72 gene plays a key role
in metabolic flexibility in times of stress/starvation (201). They found that loss of C9orf72
led to an increase in LDs, and that starvation-induced changes in lipid metabolism were
mediated by coactivator-associated arginine methyltransferase (CARM-1). Since CARM1 regulates lysosomal function and lipid metabolism, these results suggest that the
dysregulation of lipid metabolism, including the aberrant accumulation of LDs, could
contribute to ALS pathology.
Similar to studies linking LDs and peroxidation to Alzheimer’s disease, there also
appears to be a connection between LDs and cellular stress in ALS. Bailey et al. showed
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in Drosophila that ROS accumulation increased glial LD content, and that when glia were
unable to produce LDs, neuroblasts experienced peroxidative damage (193). Additional
work by Simpson et al. provided a link between LDs, peroxidation, and ALS by showing
a positive correlation between lipid peroxidation markers in ALS patient cerebrospinal
fluid and disease burden (202). Thus, LD dynamics may contribute to ALS, potentially
through a mechanism in which glia are unable to protect neurons through normal lipid
accumulation and storage mechanisms (196).

3.6.2

Huntington’s Disease

Huntington’s disease (HD) is a hereditary neurodegenerative disease caused by a
mutation in the huntingtin gene (Htt) that then codes for the Htt protein (203). Mutant Htt
contains an expanse of repeating glutamines at the N terminus, thus causing Htt
oligomerization and aggregation that leads to neuronal death. A wide range of metabolic
abnormalities characterizes HD, including alterations in autophagy (204). MartinezVicente et al. found that macroautophagy is compromised in cellular and mouse HD
models and in HD patient-derived tissues, as evidenced by the inability to recognize and
properly sequester unneeded cellular components (205). Autophagosomes in HD models
failed to recognize and load excess cargo, thus causing autophagic cytosolic components
to have a slower turnover leading to toxic accumulation of lipid in cells. They also observed
an increase in LD number and area in fibroblasts, hepatocytes, striatal cells, and primary
neurons from a HD mouse model (Qhtt mice). Furthermore, striatal tissue from advancedstage HD patients had increased oil red O staining density when compared to age-matched
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controls (205). The authors hypothesized that increased LD content in HD cells could be
due to their reduced ability to recognize and degrade excess lipid by macroautophagy.
Aditi and colleagues used transgenic Drosophila expressing the mutated form of
human Htt in neurons to better understand HD energetics (206). They found that when
compared to controls, diseased flies exhibited a characteristic pattern of weight change that
is correlated with HD progression, as evidenced by altered lipid concentrations over time.
Interestingly, and in contrast to the above study by Martinez-Vicente’s group, flies had
high levels of lipid at disease onset and low levels at the terminal stage in neurons. This
finding was also true for abdominal body fat cells, despite only expressing mutant Htt in
neurons. LD size mirrored the overall lipid levels, with large LDs being found in 3-7-dayold diseased adults and small lipid droplets forming by days 11-13 in diseased flies. These
findings suggest that mutant Htt leads to dysregulated lipid metabolism in addition to
neurodegeneration. However, further studies in both mammalian and fly models are needed
to fully elucidate the role LDs may play in the onset of HD.

3.6.3

Parkinson’s Disease

Parkinson’s disease (PD) is caused by a loss of dopaminergic neurons and leads to
abnormal brain activity and symptoms such as tremors, bradykinesia, and limb rigidity
(207). Lewy bodies are pathological hallmarks of PD that are found in pre-synaptic
terminals of neurons. These Lewy bodies contain aggregates of the α-synuclein protein
which has been shown to accumulate on LD phospholipid surfaces, slowing lipolysis of
LDs (208). Cole and colleagues also found that two mutant forms of α-synuclein, A30P
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and A53T, showed decreased capacity to reduce LD turnover in neurons compared to WT
α-synuclein. These results suggest LD turnover in neurons is contingent on proper αsynuclein function, and that LD lipolysis may contribute to PD (208). However, these
findings are complicated by the work of Outeiro and Lindquist, who found that both WT
and A53T α-synuclein caused an accumulation of LDs in yeast, whereas A30P synuclein
did not (209). These findings suggest that LDs may play a cell-specific role in PD
pathology and call for further study in this area.
Integrated genome wide association studies have found that key mechanisms of PD
pathogenesis (oxidative stress response, lysosomal function, endoplasmic reticulum stress
response and immune response) rely heavily on genes regulating lipid and lipoprotein
signaling. For example, Klemann and colleagues found that lipid and lipoprotein signaling
is regulated by the same processes involved in dopaminergic neuron death, and found
deficient signaling to be associated with increased risk for PD (210). Scherzer et al. found
that genes related to lipid metabolism and vesicle-mediated transport had the largest effects
on increasing α-synuclein toxicity in yeast (211). This same group also classified a variety
of genes related to α-synuclein expression in Drosophila, and again found that lipid-related
genes were strongly associated with this process. The authors proposed that dysregulation
in lipid processing may be an indicating factor of problems caused by A30P α-synuclein
toxicity (212).
Additional studies have begun to investigate lipid dyshomeostasis in PD more
deeply. For example, suppression of the oleic acid generating enzyme stearoyl-CoAdesaturase (SCD) was recently found to be protective against α-synuclein yeast toxicity,
and SCD knockout models in roundworms was shown to prevent dopaminergic neuron
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degeneration (213). Specific genes related to lipid regulation have also been identified.
ATPase cation transporting protein 13A2 (ATP13A2) functions in cation transport within
the cell. Mutations to ATP13A2 are associated with PD and overexpression of ATP13A2
showed a decrease in various forms of lipids in vitro (214). When looking at these findings
together, it is evident that LDs and lipid homeostasis play a more significant role in PD
than originally thought. This line of thought is supported by Fanning et al., who stated that
α-synuclein toxicity and cell trafficking defects have been associated with aberrations in
LD content and distribution (215). PD has classically been believed to be a
“proteinopathy”, but with many of the recent discoveries, lipid dyshomeostasis is rapidly
becoming one of the fundamental characteristics of this disease (215).

3.6.4

Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common form of dementia worldwide (216).
When Alois Alzheimer wrote his seminal paper in 1907 describing the case of Auguste
Deter, he noted three neuropathological hallmarks. He found “striking changes of the
neurofibrils” and “minute milliary foci caused by deposition of a particular substance in
the cortex”. He also observed glial changes and stated, “many glia include adipose
inclusions” (217, 218). While the first two findings have been studied extensively by
scientists interested in the contribution of tau and amyloid to disease progression, the
finding of glial lipid accumulation has largely been overlooked. It wasn’t until recently that
this phenomenon of increased lipid accumulation in Alzheimer’s disease was revisited and
examined. Hamilton et.al helped renew interest in this phenomenon in a report describing
increased LD formation in the SVZ of both 3xTgAD mice and human AD samples which
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correlated with defects in neurogenesis (181). Interestingly, acute administration of
intracerebral oleic acid mimicked the LD phenotype of the 3xTgAD mice, but did not alter
SVZ neuron viability, suggesting that disease-associated LD accumulation is not simply a
result of environmental lipid exposure. Derk and colleagues found a highly significant
increase in both neutral lipid and diaphanous 1 (DIAPH1) expression in myeloid cells in
AD brains (219). DIAPH1 mediates signaling for the receptor for advanced glycation end
products (RAGE), an inflammatory ROS-producing pathway. This apparent correlation
between neutral lipid accumulation and inflammatory signaling suggests that LDs may be
key players in cerebral inflammatory responses. A recent study further validated this
model, where it was discovered that astrocytes uniquely upregulate ROS management
genes, seemingly to manage the import of neuron-derived lipid oxidation products (173).
This study showed that neuronal hyperactivity alone was sufficient to initiate neuronal lipid
peroxidation, neuronal lipoprotein export, and subsequent management and storage of
peroxidized lipid as LDs in astrocytes. Further work done by van der Kant and colleagues
showed that CE, which can be incorporated into LD cores through normal LD biogenesis,
increase the accumulation of phosphorylated tau (p-tau) by reducing proteasome activity
(220). The study showed that both statins and an allosteric activator of cholesterol 24hydroxylase (efavirenz) helped lower p-tau levels in human neurons by reducing CE
concentrations, thereby providing a potential mechanistic link between LDs and AD
neuropathology.
A role for apolipoproteins as shuttles for oxidative waste from neurons has been
described in the brain (128). Additionally, different isoforms of Apolipoprotein E (ApoE)
were shown to have altered efficiency for lipid shuttling. ApoE4-laden lipoproteins
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appeared to be less efficacious at the delivery of lipotoxic products to glia than lipoproteins
associated with ApoE3.
This is particularly interesting in light of the E4 allele of APOE being the strongest
genetic risk factor for the development of late onset AD. Our group recently showed that
astrocytes expressing E4 preferentially accumulate and utilize LDs for energetic needs
(126). Additionally, transcriptional profiling of glia derived from human iPSC lines
harboring homozygous E4 or E3 alleles showed that the majority of differentially
expressed genes in astrocyte-like cells involved lipid metabolism and transport (221). This
group also found that a phenotype of E4 astrocytes included the accumulation of
intracellular and extracellular cholesterol. They hypothesized that since cholesterol is
responsible for a wide range of functions in the brain, altered cholesterol metabolism in E4
glia may be associated with pathological phenotypes in neurodegenerative disorders.
Conditioned media from E4 astrocytes has been shown to induce LDs in other cell types,
suggesting that E4 may also act extracellularly to induce LD formation (125). Finally,
neutral lipid staining of the choroid plexus in post-mortem AD brains proposed LDs as
central hubs of an ApoE-mediated complement-cascade regulation (182). The authors
found ApoE to bind to complement component 1q (C1q), a protein complex that binds
antigen-antibody complexes, on LDs in the choroid plexus. Since C1q protein is involved
in the activation of the classical complement pathway, this interaction effectively keeps the
complement system of the immune system in check at the CNS/vasculature interface.
While all ApoE isoforms showed equal binding affinity for C1q, post-mortem mice and
human E4 brains were shown to accumulate LDs more abundantly. Interestingly, these
lipid deposits significantly correlated with neuropathological staging of AD, pointing to
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APOE regulation of the complement cascade at the choroid plexus niche as a novel
hypothesis for AD pathogenesis.

3.6.5

Hereditary Spastic Paraplegia

Hereditary spastic paraplegia (HSP) is a group of inherited neurological disorders
that cause muscle weakness and tightness, primarily in the legs, through the degeneration
of long corticospinal axons (222, 223). Studies of HSP-causing proteins suggest a link
between lipid metabolism and the development of disease. For example, DDH2 domain
containing protein 2 (DDHD2) is a triglyceride hydrolase in the brain that is implicated in
recessive complex HSP. The systemic genetic knockout and pharmacological inhibition of
DDH2 resulted in large-scale accumulation of LDs within the CNS, but not elsewhere
(224). These data indicate a link to TAG metabolism, as the inhibition of DDHD2 affects
lipid homeostasis and LD number.
One of the most common genetic mutations involved in HSP occurs in the
microtubule severing protein spastin (200, 225) . The M1 isoform of spastin contains a LD
targeting sequence which contributes to protein targeting to LDs and LD sorting at the ER.
Additionally, spastin deficiency in Drosophila and C.elegans altered LD number and TAG
content. This study suggests that LD processing may contribute to the pathogenesis of HSP
(225). Additionally, a study by Arrabit et al. further identifies spastin as a regulator of LD
dispersion and dynamics. This group showed that mutations in the spastin M1 isoform
induced ER reorganization in HeLa cells. This reorganization subsequently disrupted
spastin’s ability to disperse LDs throughout the cell and aberrantly modulated neutral lipids
and phospholipids on membranes throughout the muscle and brain (226). Furthermore,
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embryonic zebrafish cells that were treated with oleic acid (a common method to induce
LD formation) indicated that a loss of spastin resulted in a higher number of smaller LDs,
therefore suggesting differential generation and/or dispersion of LDs (226). In addition to
identifying potential new HSP biomarkers, this study also proposes that HSP-causing
mutations impacts lipid profiles and LD networks.
Several groups have also forged a connection between the protein spartin and LD
regulation. Spartin is a multi-functional unit that associates with LD, and a lack of spartin
expression contributes to a HSP form called Troyer syndrome (227). In one study by
Edwards et al., spartin surrounded LD clusters in oleic acid treated HeLa cells, thus
suggesting that spartin is recruited to LDs (228). Additionally, in spartin knockout mice,
female mice had increased LDs number and higher perilipin protein levels in adipose tissue
(229). Hooper and colleagues further demonstrated an interaction between spartin and LDs.
Their experiments in HeLa cells showed that spartin binds to and recruits the ubiquitin
ligase atrophin-1-interacting protein 4 (AIP4) to LD. This interaction subsequently
promotes the ubiquitination of PLIN2. Since PLIN2 resides on LD membranes and
regulates TAG turnover, spartin may play a role in LD regulation in cells and contribute to
Troyer syndrome pathology (227). Furthermore, another group reported binding
interactions between spartin and protein kinase C interacting proteins (ZIPs) at the surface
of LDs. Spartin-expressing HEK-293 cells exhibit co-localization of spartin with ZIP1 and
ZIP3 on LDs as shown by superimposition of spartin GFP-tagged fluorescence and Oil Red
O fluorescence. (230). Interestingly, in the absence of spartin, no ZIP proteins were
detected on the LD surface (230). These collective findings suggest that impaired LD
metabolism might be one mechanism that contributes to Troyer Syndrome.
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3.7

Regulation of LDs in the brain
Lipid droplets in the brain may be regulated differently than more traditional LD

niches. DDHD2 action in HSP implicates this protein as an important player in CNS lipid
metabolism but also shows a dichotomy between peripheral LDs and central LDs. The
BBB forms a tight and regulated gate for lipid import and export into the brain, and thus
there are separate pools of lipids that constitute the intracellular LDs located in cells in the
CNS versus the periphery. Lipid contents of the cell types that make up the BBB appear to
regulate its permeability (184, 231). Since enzyme mutations of key lipases are manifested
differently in the brain and given the existence of lipid-regulatory mechanisms between the
periphery and the CNS, it is possible that the two pools are controlled by separate
mechanisms. Investigators should be cautious when applying canonical peripheral LD
pathways to brain LD biology until more evidence emerges for conserved physiological
pathways between the brain and the periphery.
Sex-specific regulation of lipid metabolism and LDs in the brain should also be
considered. In one study, neurons of male rats were shown to be more vulnerable to
starvation than neurons of female rats, with male neurons exhibiting decreased
mitochondrial respiration, increased autophagosome formation, and increased cell death
when compared to females (232). On the other hand, the same study showed that female
tolerance of starvation conditions was associated with increases in fatty acid content and
LD formation in order to prolong cell survival. These findings suggest that central LD
dynamics may be sex dependent. Potential sex differences should be considered in future
studies in order to better understand the contribution of sexually dimorphic features to
cerebral LD metabolism and its relevance to disease susceptibility and pathology.
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3.8

Future directions and concluding remarks
Several important knowledge gaps remain in our understanding of the role of LD

biology in the pathophysiology in neurodegenerative disease. One important future
direction for the field is to better understand the full composition of lipids comprising brain
LDs – in both healthy and diseased states. A clearer picture would likely be revealed by
the precise distribution of lipid classes in distinct brain regions, as well as in specific
neurodegenerative diseases. However, their relatively small size and the diversity of LDs
by age, cell type, and disease type complicate the compilation of a lipid profile of LDs.
Additionally, in vivo analysis of lipids in general is challenging, as they are a diverse class
of macromolecules and are relatively insoluble (233). However, improved techniques in
mass spectrometry provide new ways to document the lipid composition in LDs. For
example, matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDIIMS) allows for anatomically-specific direct detection of lipids within membranes through
the production of lipid-derived ions (234). Since MALDI can detect phospholipids,
sphingolipids, and glycerolipids, this technique provides the opportunity for an in depth
and spatially-resolved profile of LDs (235). The continued use of powerful imaging
techniques such as MALDI will be important to providing a better understanding of lipid
class distribution in cerebral LDs.
LDs are cellular fuel stores, markers of inflammation, signaling hubs, protective
waste reservoirs for hyperactive neurons, products of lysosomal dysregulation, and
hallmarks of age. With such a wide array of roles, it is not surprising that LD accumulation
has been linked to trauma, neurodegeneration, and aberrant cerebral metabolism. LDs are
promising targets for novel investigations of neurological disease diagnosis and
therapeutics. Therapeutic treatments could be targeted at restoring lipid balance, decreasing
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droplet levels, or improving other aspects of lipid metabolic pathways. Further study on
LDs and lipid metabolism will be essential in advancing our knowledge of cerebral
metabolism, as well as the multifaceted etiologies of neurological disease.

Table 3.1 Lipid droplet-related literature pertaining to the brain. These papers have been
classified by the model organism that was used, area of the brain that was studied, and cell
type of focus.
Model
Area of
Author and
Cell
Organi
the
Year of
Summary of Findings
Type
sm
Interest
Publication

(236)

Large, electron dense LD-like
vesicles were visible in some
dendrites located in cortical layers
that had abundant degeneration.

Astrocy
te

(237)

A small amount of sudanophilic
LDs were observed in the
thalamus of a patient with NasuHakola disease.

Medial
Temporal Various
Cortex

(219)

DIAPH1 localized to locations of
LD accumulation in myeloid cells.

(238)

Amyloid inclusions were often
associated with LDs in close
contact to fibril bundles.

(239)

A brain biopsy found ballooned
neurons filled with oligolamellar
cytosomes and LDs.

(240)

Demyelination with cuprizone and
myelin debris contributed to LD
formation. LD volume and number
was highest in richly myelinated
corpus callosum.

Frontal
Cortex

Neuron

Frontal
Lobe

Human
Choroid
Plexus

Whole
Brain

Adrenal
Cortical

Neuron

63

Cerebral
Cortex

Hippoca
mpus

Neuron

(241)

Injection of squalene led to
accumulation of LDs in the myelin
sheaths of neurons.

(242)

Exposure to excess oxygen caused
neuronal necrosis and was more
severe in young rats. Neurons
accumulated electron dense LDs.

(208)

The protein alpha-synuclein was
less effective at regulating
triacylglycerides turnover and
showed variable distribution on
LDs.

Neuron

Median
Eminenc
e

Tanycyt
e

(243)

As rats aged, the number and size
of LDs increased. Degenerate
bodies also developed with age
and were interspersed with large
LDs.

Olfactory
Bulbs

Neuron
s

(244)

LDs are manifestations of cell
response to injury.

Perineuri
um

Perineu
rial
Glia

(245)

LD formation was found to be an
early reactive change to ischemia
in perineurial, endothelial, and
Schwann cells.

Pineal
Gland

Pinealo
cyte

(Johnson,
1980)

Removal of the hypophysis led to
a significant loss of LDs in the
pineal gland.

(246)

Following the withdrawal of
estrogen from estrogen primed
male rats, folliculo-stellate cells
became packed with LDs.

(247)

Supraopticus and paraventricularis
neurons showed an increased
number of LDs following
ischemia.

Rat

Pituitary
Gland

Follicul
ostellat
e

Neuron

64

Striatum

Neuron

Rat
(cont.)
Whole
Brain

LDs were observed in neurons of
rats injected with kainic acid to
simulate HD.

(249)

Macrophages and astrocytes
played important roles in lipid
metabolism.

(250)

LDs reached a maximum at 7 days
following middle cerebral artery
occlusion and were localized
mainly within microglia in the
ischemic core and within
astrocytes in the penumbra.

Glia

Astrocy
te
Choroid
Plexus

(248)

(251)

Macrop
hage

(252)

About half of the macrophages in
the brains studied were distended
due to excess LDs or foamy
aggregations.

Various

(253)

LDs appeared in the choroid
plexus with increased age.

(254)

Inhibition of diacylglycerol
acyltransferase blocked oleic acid
induced LD accumulation and
lipotoxic cell death in astrocytes.

(255)

Lipid species were elevated in an
AD mouse model and impeded
macroautophagy and clearance of
lipids.

(256)

Neuronal loss and glial cell
proliferation was associated with
changes in lipid related transcripts.

(173)

Neurons expelled fatty acids in
association with ApoE-positive
lipid particles. Nearby astrocytes

Mouse

Astrocy
te
Cortex
Autolys
osome

Hippoca
mpus

LD-like droplets were frequently
found in several brain regions of
senescence-accelerated mice.

Neuron,
glia
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then engulfed them and stored
them as LDs.

Microgl
ia

Astrocy
te

Hypothal
amus
Mouse
(cont.)

(171)

A LD-accumulating subset of
microglia were defective in
phagocytosis, produced high levels
of ROS, and secreted proinflammatory cytokines.

(187)

Hypothalamic astrocytes
accumulated LDs and had
increased astrogliosis markers
along with increased levels of
inflammatory cytokines.

(257)

LD signal in the tanycyte layer
was higher in high fat diet mice
and returned to normal under
telmisartan treatment.

(258)

A high fat diet increased the
number and size of LDs in
tanycytes.

(259)

Lipid dysregulation in PD
involved upregulated expression of
Plin4, increased intracellular LD
deposition, and loss of neurons.

Tanycyt
e

Mesence
phalon

Neuron

Neostriat
um

Various

(260)

Pericytes contained LDs in the
neostriatum, indusium griseum,
and anterior commissure at
varying ages.

Supraopti
c
Nucleus

Neuron

(261)

Neurons stimulated with CDPcholine displayed LDs in their
cytoplasm.

(180)

Cells with increased numbers of
large LDs showed heighted signs
of quiescence and metabolic
disturbance

(181)

Impaired fatty acid metabolism
suppressed neural stem cell
activity while oleic acid signaling

Subventri
cular
Zone

Neuron
al stem

66

interference rescued stem cell
regenerative function
White
Matter

Whole
Brain

(262)

Macrophages in mice CreutzfeldtJakob disease were filled with
LDs.

Glia

(263)

Mice fed high fat diets had
increased LDs and cells with more
LDs were more likely to be
senescent. Clearing senescent cells
from restored neurogenesis and
alleviated anxiety related behavior.

Neuron

(264)

Postmortem AD brains and 3xTg
mice were shown to accumulate
neutral lipids in ependymal cells.

(175)

Cerebral lipid loaded cells
displayed a variety of distinct
phenotypes based on their location
in the brain. Lipid loaded cell
numbers increased with age.

Various

Mouse
(cont.)

Whole
Brain
Various

Cortex

Glia

(265)

ND23 knockdown in glial cells
created massive LD accumulation
and induced brain degeneration.

Cortex

Glia

(266)

LDs were localized in glial cells
and were enriched in the cortex.

Whole
brain

Neuron
al stem

(267)

LDs played an antioxidant role in
neural stem cells by reducing ROS
and protecting against
peroxidation.

Hypothal
amus

Neuron

(268)

Large LDs were found in CSF
contacting neurons.

(192)

ROS and neuronal mitochondrial
dysfunction contributed to LD
accumulation prior to the onset of
neurodegeneration.

Fly

Various

Glia

67

Other

Various

(269)

Air pollution caused ApoEpositive LDs to be deposited in
smooth muscle cells and pericytes.

(179)

GRAF1a was found on LDs in
primary glial cells that were fed
oleic acid. Overexpression of
GRAF1a promoted LD clustering
and perturbed lipolysis.

(185)

LPS treated microglia accumulated
LDs and Plin2 colocalized with
droplets.

(186)

TGRL lipolysis increased the BBB
transfer coefficient, induced
droplet formation in astrocytes,
activated cell stress pathways, and
increased inflammatory cytokine
levels.

(126)

E4 astrocytes have increased lipid
content compared to E3 astrocytes.
LDs provide energy substrates.

HeLa

(208)

PD mutations in a-synuclein
showed less variable LD
distribution and less effective TG
turnover. Synuclein formed
oligomers within cells and
associated with droplets.

N41

(270)

Cells treated with LPL
accumulated lipid into droplets.

Neuron

Glia

In vitro

In vitro
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Figure 3.1 A diagram of the molecular structure of a standard lipid droplet (LD) along with
a software reconstruction of a microscopic image of astrocytes in vitro containing LDs
(highlighted in pink; LipidSpost) surrounding a nucleaus (in blue; DAPI).
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Figure 3.2 A timeline of selected lipid droplet discoveries as they relate to
neurodegenerative disease
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CHAPTER 4. APOE4 ALTERS FATTY ACID METABOLISM AND INCREASES
LIPID DROPLET FORMATION IN ASTROCYTES
[This chapter consists of material adapted from a published manuscript: Farmer BC,
Kluemper JC, Johnson LA. Apolipoprotein E4 Alters Astrocyte Fatty Acid Metabolism
and Lipid Droplet Formation. Cells. 2019 Feb. PMID: 30791549. For supplementary
materials pertaining to this chapter, see appendix 1.]

ABSTRACT
Lipid droplets (LDs) serve as energy rich reservoirs and have been associated with
apolipoprotein E (APOE) and neurodegeneration. The E4 allele of APOE (E4) is the
strongest genetic risk factor for the development of late onset Alzheimer’s disease (AD).
Since both E4 carriers and individuals with AD exhibit a state of cerebral lipid
dyshomeostasis, we hypothesized that APOE may play a role in regulating LD metabolism.
We found that astrocytes expressing E4 accumulate significantly more and smaller LDs
compared to E3 astrocytes. Accordingly, expression of perilipin-2, an essential LD protein
component, was higher in E4 astrocytes. We then probed fatty acid (FA) metabolism and
found E4 astrocytes to exhibit decreased uptake of palmitate, and decreased oxidation of
exogenously supplied oleate and palmitate. We then measured oxygen consumption rate,
and found E4 astrocytes to consume more oxygen for endogenous FA oxidation and
accumulate more LD-derived metabolites due to incomplete oxidation. Lastly, we found
that E4 astrocytes are more sensitive to carnitine palmitoyltransferase-1 inhibition than E3
astrocytes. These findings offer the potential for further studies investigating the link
between astrocyte lipid storage, utilization, and neurodegenerative disease as a function of
APOE genotype.
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4.1

Introduction
Apolipoprotein E (apoE) is associated with circulating lipoproteins, specifically very

low-density lipoproteins and high-density lipoproteins (271). The polymorphic APOE gene
encodes for three isoforms, E2, E3, and E4, with frequencies of 8%, 77%, and 15%,
respectively, in the general US population (59). E4 is the strongest genetic risk factor for
late onset Alzheimer’s disease (AD) (59). In addition to established effects on AD
neuropathology, APOE genotype is also recognized as a strong modulator of cerebral
metabolism (4, 68, 272, 273). In fact, cognitively normal E4+ individuals demonstrate
alterations in cerebral fatty acid (FA) and carbohydrate metabolism congruent with AD
patients (3, 4). Understanding the metabolic effects of apoE in the brain may be a critical
step in discovering the underlying mechanism(s) of E4-driven AD risk.
The brain is one of the largest site of apoE synthesis, second to the liver (274). The
majority of brain apoE is astrocyte derived, though under certain conditions such as trauma,
neurons and microglia also synthesize apoE (275). ApoE binds to receptors of the lowdensity lipoprotein receptor family, which are expressed on astrocytes as well as neurons
(276). Astrocytes aid in shuttling lipids from the blood-brain barrier (BBB) to neurons by
both binding and internalizing BBB permeable FAs from the endothelial cells, and loading
lipid-free apoE with cargo through action of the ATP-binding cassette transporters such as
ABCA-1 (277, 278). Therefore, astrocytes are key players in the lipid uptake-apoElipidation axis, and are vital to maintaining brain lipid homeostasis and proper neuronal
function. Not only are astrocytes critical for uptake and export of FAs and lipid-loaded
lipoproteins, they also are the main cell population mediating β-oxidation of FAs in the
brain (279, 280). Astrocytes contain a higher relative density of mitochondria than the
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surrounding neuropil, giving them superior machinery to oxidize FA (281). Furthermore,
carnitine palmitoyltransferase-1 (CPT-1), an essential enzyme for the beta-oxidation of
long chain FA, is preferentially expressed in astrocytes compared to neurons, microglia,
and oligodendrocytes (282). Recent studies clearly show that the brain does in fact utilize
a significant amount of FAs, with some reports estimating FAs are responsible for up to
20% of cerebral ATP generation (280, 283).
Lipid droplets (LD) are organelles containing triacylglycerols and cholesterol esters
surrounded by a layer of amphipathic lipids and associated proteins. Once thought to be
inert cellular depots of fat, lipid droplets are now considered to be dynamic organelles that
play a role in various metabolic diseases (139, 284). Indeed, the overaccumulation of LDs
has been linked to atherosclerosis, metabolic syndrome, cancer, and diabetes (285, 286).
However, only recently have studies begun to address the potential pathological
consequences of abnormal LD accumulation in the brain (284). Although low amounts of
LD are observed in the brain under normal conditions (165), studies have noted increased
LD content in neurodegenerative conditions such as Parkinson’s (208) and AD (181, 219).
Interestingly, Alois Alzheimer noted glial lipid accumulation in his first description of AD
pathology (218), but this has gone relatively unstudied apart from a few reports linking
LDs and AD (128, 181). Recent findings suggest that glial cells within the brain form LD
as a function of neuronal stress, and in the fly brain this process is apoE dependent (128).
Astrocyte derived E4 has been shown to promote LD formation in fibroblasts (287), and
iPSC-derived astrocytes expressing E4 exhibit increased lipid storage in the form of
cholesterol (34). E4 astrocytes also show varied expression of numerous genes associated
with lipid metabolism and transport, compared to those expressing E3 (34). However,
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apoE-isoform specific modulation of LD accumulation and FA metabolism in astrocytes
has not been previously described.
In this study, we characterize an increase in lipid droplet formation and endogenous
FA utilization in E4 astrocytes, as well as decreased uptake and oxidation of exogenous
FAs. These lipid metabolism events influenced by APOE offer both targets for future late
onset AD therapies and potential for more studies analyzing the metabolic effects of APOE
in the brain.

4.2

Methods
4.2.1

Cell Culture

E3 and E4 expressing astrocytes were derived from targeted replacement mice
expressing human APOE3 or APOE4 (kind gift from Dr. David Holtzman). These cell lines
secrete apoE in high density lipoprotein-like particles at equivalent levels to primary
astrocytes from targeted replacement APOE knock-in mice and have been relied upon for
studies of APOE’s role in astrocyte metabolism by many groups (91-93, 97). Cells were
maintained in Advanced Dulbecco's Modified Eagle Medium (DMEM) (Gibco, Carlsbad,
CA, USA) supplemented with 1 mM sodium pyruvate, 1× Geneticin, and 10% fetal bovine
serum. For imaging experiments, cells were grown on sterilized coverslips in 6-well plates
pre-treated with poly-L. For lipid loading experiments, 250 µM oleate pre-conjugated to
bovine serum albumin (BSA) (Sigma, St. Louis, MO, USA) was added to the media 24 h
prior for lipid droplet induction as previously described (288).
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4.2.2

Western Blotting

Cells were lysed on ice using radioimmunoprecipitation assay Buffer (Thermo
Fisher Scientific, Waltham, MA, USA) with 1× proteinase inhibitor (Sigma, St. Louis, MO,
USA ). Protein concentration was determined by Pierce bicinchoninic acid (BCA) protein
assay (Thermo Fisher Scientific, Waltham, MA, USA). 20–30 µg of protein was diluted
with 2× Laemmli Sample Buffer (Bio-Rad Laboratories, Hercules, CA, USA) and heated
at 100 °C for 10 min. Protein samples were then loaded on 4–20% PROTEAN TGX gels
(Bio-Rad Laboratories, Hercules, CA, USA) for SDS-PAGE. Gels were transferred using
a Trans-Blot Turbo Transfer system (Bio-Rad Laboratories, Hercules, CA, USA ) onto
polyvinylidene fluoride membrane. Membranes were then blocked for 2 h in 1% casein
and then incubated overnight in primary antibody solution (1:1000 PLIN-2 (Novus
Biologicals, Centennial, CO, USA); 1:1000 APOE (Abcam Inc., Cambridge, MA, USA);
1:1000 β-actin (Novus)) at 4 °C. Membranes were then washed three times for five minutes
each with PBS, pH 7.4, 0.05% Tween-20, and then incubated with secondary antibody
solution (1:10,000 Goat α rabbit IR 680 (LI-COR, Lincoln, NE, USA); 1:5000 goat α
mouse IR 800 (LI-COR)) for 2 h at room temperature. Membranes were then washed as
before, with an additional two 10 min washes in PBS. Images were acquired on a LI-COR
Odyssey Infrared Scanner. Resulting images were exported to ImageJ for blot densitometry
and quantification.
4.2.3

Lipid Droplet Imaging

After lipid incubation, coverslips were lifted from the wells and cells were fixed for
15 min in 4% PFA, washed 1× with PBS, and incubated for 30 min in 1:1000 LipidSpot
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(Biotium, Fremont, CA, USA). Coverslips were then mounted onto slides using
Fluoroshield mounting media with DAPI (Abcam). Slides were kept at 4 °C. Wide field
images were obtained on a Nikon Ti2 microscope using a 20× objective. Single cell images
were obtained on a Nikon A1R Laser Scanning Confocal Microscope (Nikon, Tokyo,
Japan) using an oil immersed 100× objective. Astrocytes were selected in the 405 channel
(DAPI-stained nuclei) and then the 610 channel was added (LipidSpot-stained LDs) and
the images were captured. Z-stacks were taken in a range of 10 µM, 40 images per stack.
3-D reconstructions were processed in Imaris 9.2 software using the surfaces module to
obtain statistics for lipid droplets. Experimenter was blind to slide identity and slides were
processed in random order under identical microscope settings.
4.2.4

Fatty Acid Uptake Assay

Astrocytes were plated at 50,000 cells/well in CytoStar T plates (Perkin Elmer,
Waltham, MA, USA) and allowed to grow to confluency. Media was aspirated, and new
glucose free media supplemented with either 0.5 µCi/mL

14C-palmitate

or

14C-oleate

(Perkin Elmer) was added to the wells. Scintillation bead technology in the wells emitted
light proportionate to the cellular uptake of the FA (289). Radioactivity counts were read
on a Microbeta 2 Microplate Counter (Perkin Elmer) and normalized to protein content in
the well using a BCA assay (Thermo Fisher Scientific, Waltham, MA, USA).
4.2.5

Fatty Acid Oxidation Assay

Astrocytes were plated in a 24-well plate at 300,000 cells/well and allowed to grow
to confluency for 24 h. Using a previously published protocol (290), cells were then
incubated with 0.5 µCi/mL [1-14C] palmitate or 0.5 µCi/mL [1-14C] oleate for 24 or 3 h.
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For the pulse experiment (exogenously supplied FA) radiolabeled FAs were added in
nutrient depleted media (Glucose Free DMEM; 5% FBS) for 3 h. Buffered

14CO2

in the

media was then liberated by addition of 1 M hydrochloric acid and captured on a filter
paper disc pre-soaked with 1N sodium hydroxide. For the pulse chase experiment
(endogenous FA), radiolabeled FAs were added in nutrient rich media (25 mM Glucose;
10% FBS) for 24 h, then aspirated and nutrient depleted media was added to promote
oxidation of fatty acid from intracellular lipid pools. Radioactivity of the filter paper was
measured in a Microbeta 2 Microplate Counter after addition of 3 mL Ultima-Gold
Scintillation Fluid. Acid soluble metabolites, which represent incomplete oxidation of the
fatty acids, were extracted from the media and cellular fractions. Total protein from each
well was assayed using a BCA assay (Thermo) and all radioactivity measures were
normalized to protein content.
4.2.6

Seahorse Extracellular Flux Analysis

Astrocytes expressing E3 or E4 were seeded in a 96-well microplate at 50,000
cells/well and left to form a monolayer overnight. Media was aspirated and 135 µL of
limited nutrient running media (DMEM; 5 mM glucose, 2.5 mM carnitine, 5 mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid) was added to each well and allowed to
incubate for 1 h. Then 30 µL of 1 mM sodium palmitate complexed to BSA (6:1 molar
ratio) or BSA alone was added to wells according to group assignment, at which point the
oxygen consumption rate (OCR) was determined by a Seahorse Extracelluar Flux Analyzer
xF96 (Agilent, Santa Clara, CA). At each successive 18 min, an injection of 200 µM
etomoxir, 1 µM oligomycin, or 1 µM Rotenone | Antimycin was added to each well to
inhibit carnitine palmitoyltransferase-1 (CPT-1), ATP synthetase, or complex I and III
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respectively. OCR was measured every 6 min. Values were normalized to protein content
in each well by a BCA Assay (Thermo). OCR from endogenous FA oxidation was
determined by calculating the average etomoxir effect in BSA treated astrocytes (Equation
(1)).
̅̅̅̅̅̅𝐸𝑛𝑑𝑜 𝐹𝐴𝑂 = 𝑂𝐶𝑅
̅̅̅̅̅̅𝑃𝑟𝑒−𝐸𝑡𝑜 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑂𝐶𝑅
̅̅̅̅̅̅𝑃𝑜𝑠𝑡−𝐸𝑡𝑜 𝐶𝑜𝑛𝑡𝑟𝑜𝑙
𝑂𝐶𝑅

(1)

OCR from exogenous FA oxidation was determined by calculating the average difference
in basal OCR in the palmitate treated astrocytes versus the basal OCR in BSA treated
astrocytes (Equation (2)).
̅̅̅̅̅̅
𝑂𝐶𝑅𝐸𝑥𝑜 𝐹𝐴𝑂 = ̅̅̅̅̅̅
𝑂𝐶𝑅𝑃𝑟𝑒−𝐸𝑡𝑜 𝑃𝐴 − ̅̅̅̅̅̅
𝑂𝐶𝑅𝑃𝑟𝑒−𝐸𝑡𝑜 𝐶𝑜𝑛𝑡𝑟𝑜𝑙
4.2.7

(2)

Statistical Analysis

All data are expressed as mean ± standard error. Comparisons between two groups
were analyzed by t-test. Multiple groups and/or multiple time points were analyzed using
ANOVAs (Prism, Graphpad, San Diego, CA, USA), or repeated measures ANOVA (time
× groups) (SPSS). Statistical significance was determined using an error probability level
of p < 0.05 corrected by a false discovery rate (FDR) analysis (Benjamini Hochberg
method).
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4.3

Results
4.3.1

E4 Astrocytes Display Increased LD Count, Increased Cellular LD Volume,
Decreased LD Size

We first asked if APOE influences lipid storage within astrocytes. To answer this,
we lipid-loaded E3 and E4 astrocytes with 250 μM oleate for 24 h, stained for neutral LDs
(Figures 1A and S3A), and quantified LDs per cell (Figures 1B and S3B). E4 astrocytes
showed a significant increase in the number of LDs, both at basal levels and in a FA-rich
environment, compared to E3. (Figure 4.1B) Total LD volumes within the cell were also
analyzed, and E4 astrocytes held significantly more lipid volume under lipid loaded
conditions compared to E3. (Figure 4.1C). Furthermore, expression of perilipin-2 (PLIN2), a LD associated protein, was increased in E4 astrocytes in an FA-rich environment
compared to E3. (Figure 4.1D–E; Appendix 2.1).
To determine LD size and distribution, LDs in individual cells were rendered using
Imaris software under control and lipid-loaded conditions (Figure 4.2A), and volumes were
quantified (Figure 4.2B–D) and binned using 0.1 µm as a bin size. It was found that E4
astrocyte LDs were on average 54.8% smaller on a volume per droplet basis than E3s under
control conditions, and 33.7% smaller when lipid-loaded. Together, these results suggest
that E4 astrocytes form more LDs than E3 astrocytes regardless of FA exposure, as
reflected in increased expression of PLIN-2 and an increased LD count.
4.3.2

E4 Astrocytes Take Up Less Palmitate
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Hypothesizing that an increase in lipid storage may be a result of increased uptake
of FAs, we next sought to determine if APOE regulates astrocyte FA uptake. Using a
scintillation proximity assay and treating with 14C-labeled FAs, we found E4 astrocytes to
take up significantly less palmitate (Figure 4.3A–B), with no significant difference in
oleate uptake (Figure 4.3C). Conversely, there was a trend toward increased oleate uptake
in E4 astrocytes, with cumulative uptake slightly higher when expressed as the area under
curve despite lacking statistical significance. (Figure 4.3D) These data suggest that APOE
isoforms may modulate FA uptake in astrocytes dependent on the FA species.
4.3.3

E4 Astrocytes Oxidize Less Exogenous Fatty Acids

We next examined how APOE might regulate FA oxidation in astrocytes. We first
assessed how E3 and E4 astrocytes oxidize exogenously supplied FA. We treated cells with
radiolabeled palmitate or oleate for 3 h in a nutrient depleted media, and captured the
oxidation product CO2, as well as incompletely oxidized products of FA metabolism in the
form of acid soluble metabolites (ASM). (Figure 4.4A). We found that E4 astrocytes
oxidize significantly less exogenously supplied oleate and palmitate than E3 astrocytes
(Figure 4.4B), and instead accumulate significantly more metabolites that are acid soluble
(Figure 4.4C–D); these ASM include ketone bodies, acyl carnitines, citric acid cycle
intermediates, and FA less than six carbons in length (290). We found an increased
concentration of these ASM inside E4 cells (Figure 4.4C). We also found an increased
concentration of ASM in the media (Figure 4.4D), suggesting that E4 astrocytes may export
more FA metabolites than E3s. Using Seahorse Extracellular Flux Analysis, we then
measured the oxygen consumption rate (OCR) before and after inhibition of CPT-1 in E3
and E4 astrocytes supplied with palmitate in the media (Figure 4.4E). We found E4
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astrocytes to exhibit a lower OCR compared to E3 at all time points (Figure 4.4E). This
lower OCR is likely primarily due to a decreased rate of glucose oxidation, as E4 is strongly
associated with a phenotype of glucose hypometabolism (4, 48). When we specifically
calculated the contribution of FA oxidation to OCR by comparing basal OCR in palmitate
treated versus BSA treated astrocytes, we found that E4 astrocytes utilize significantly less
exogenously supplied FA as part of their basal respiration. (Figure 4.4F)
Since E4 astrocytes showed a significant increase in LD accumulation, we next
studied how APOE modulates FA oxidation from intracellular FA pools. Knowing that
incubation with oleate for 24 h induces LD formation, we “pulsed” E3 and E4 astrocytes
with radiolabeled FAs for 24 h to incorporate the radiolabel into LDs (Figure 4.5A). We
then aspirated the media, washed with PBS, and captured oxidation and non-oxidation
products of the intracellular FAs after a 4 h “chase”. Interestingly, in contrast to the
oxidation of exogenously supplied FA, E3 and E4 astrocytes showed no difference in CO2
production from intracellular pools of oleate or palmitate (Figure 4.5B). Quantification of
ASMs of intracellular palmitate and oleate revealed that E4 astrocytes once again exported
significantly more ASM into the media (Figure 4.5C), and have similar levels within the
cells (Figure 5D). We next quantified OCR using Seahorse in E3 and E4 astrocytes that
were incubated in serum free media and not supplied with exogenous FA (Figure 4.5E),
assuming the only source of FA would be from intracellular LDs. We found that the OCR
in E4 astrocytes that could be attributed to oxidation of endogenous FA was significantly
higher than E3 astrocytes, suggesting that while CO2 production is similar between
genotypes, E4 astrocytes seem to consume more oxygen from the metabolism of
intracellular FAs (Figure 4.5F). Together these data suggest that APOE alters FA oxidation
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in astrocytes, and that these effects differ depending on the source of FAs (endogenously
stored as LD vs exogenously supplied in media)

4.3.4

E4 Astrocytes Are More Sensitive to CPT-1 Inhibition

Since CPT-1 is the rate-limiting enzyme of fatty acid oxidation, we hypothesized
that E3 and E4 astrocytes may exhibit varying responsiveness to CPT-1 inhibition. Using
Seahorse, we measured OCR before and after CPT-1 inhibition with etomoxir and assessed
the percent change in OCR from baseline in E3 and E4 astrocytes pretreated with palmitate
and the non-pretreated control cells (Figure 4.6A). We found that E4 astrocytes have a
significantly larger drop in OCR after CPT-1 inhibition compared to E3 astrocytes in both
pretreated and control cells, suggesting an increased reliance on FA oxidation for overall
OCR (Figure 4.6A).
To determine if CPT-1 inhibition results in APOE genotype specific effects on
palmitate and oleate oxidation, we used a 14CO2 trap approach and found E4 astrocytes to
exhibit a greater fold change in oxidation of palmitate from the baseline after CPT-1
inhibition (Figure 4.6B). However, we saw no differences between genotypes with regards
to the etomoxir effect on oleate oxidation (Figure 4.6B), again suggesting these APOE
effects may be specific to certain FA species.

4.4

Discussion
Lipid droplets in astrocytes serve to both sequester fatty acids that would otherwise

be cytotoxic if free in the cytoplasm and to offer an energy rich and accessible pool for
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cellular metabolic needs in times of starvation and stress. Recent studies of AD brain tissue
have demonstrated an increase in LDs (181, 219). ApoE is an important component of
peripheral and central nervous system lipoproteins, which share many biochemical features
with LDs (139). The E4 allele of APOE is a critical genetic risk factor for late onset AD,
and is strongly associated with a number of metabolic abnormalities (4, 34, 42, 47).
However, the link between E4 and LD biology has not been widely explored. In the current
study, we characterized a number of apoE isoform specific differences in LD formation
and FA utilization in astrocytes.
We found that E4 astrocytes form many small LDs compared to the few large LDs
observed in E3 astrocytes. The structural makeup of LDs could be a contributor to overall
LD size. Surfactant lipids such as phosphotidylcholine (PC) are known to stabilize LD
emulsions, while more fusogenic lipids, such as phosphatidic acid, promote LD
coalescence (139, 291). Our group previously showed that E4 mice brains differ in various
lipid concentrations using an unbiased metabolomics approach(51). Interestingly,
Heinsinger et al. recently showed that the apoE isoforms are associated with varying sizes
of CNS lipoproteins, with E4 individuals and astrocytes synthesizing smaller apoEassociated lipoprotein particles (292). As the structure and makeup of LDs and lipoproteins
are similar, it is possible that E4 promotes smaller spherical lipid carriers whether that be
inside or outside the cell. Overall isoform specific effects on FA metabolism could also be
a result of differing total concentrations of apoE. E4 astrocytes are known to secrete less
apoE into the media and have less intracellular apoE (Figure S2) (97), and E4 brains from
targeted replacement mice have less apoE (293). Whether the lower quantity of apoE4 in
E4 carriers is related to disease pathogenesis is unknown.
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LD associated proteins, such as perilipins, serve to stabilize the LD from excessive
lipolysis. Loss of perilipin-2 has been associated with an increase in endogenous fatty acid
oxidation (294). We found that E4 astrocytes exhibit increased expression of perilipin-2,
decreased exogenous FA oxidation, and increased oxygen consumption from endogenous
fatty acid oxidation. Overexpression of PLIN2 has been liked to a decrease in glucose
uptake by LD sequestration of key regulators of glucose transporters (295). In unpublished
work, our group found that E4 down-regulates astrocyte glucose metabolism, much like
the effects reported in neuronal models of apoE overexpression (47). It may be that the
energetic needs of an E4 astrocyte in the absence of robust glucose metabolism overpower
the inhibitory effect of PLIN2 on LD lipolysis. The overexpression of PLIN2 has also been
shown to increase LD formation in various cell types (190, 296, 297). This is congruent
with our findings in regards to E4 astrocytes, where an increase in LD number paralleled
with increased PLIN2 expression. In hepatocytes, increased levels of reactive oxygen
species (ROS) prompt increased PLIN2 expression subsequent LD formation (190). ROS
has been linked to LDs in glia in a Drosophila model as well, and this process was found
to be apoE dependent (128, 192). Oxidative stress as an inducer of LDs in astrocytes as a
function of APOE deserves further investigation in light of the poor anti-oxidant capacity
of E4 (298). Alternatively, the presence of many small droplets as opposed to larger
droplets could be a result of increased FA oxidation resulting from LD turnover. More
studies are needed in CNS in vitro models to define LD metabolism and how it may differ
from peripheral LD metabolism.
E4 carriage in humans seems to promote an “accelerated AD” status, particularly in
terms of cerebral glucose metabolism (4). Namely, as individuals transition through mild
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cognitive impairment to AD, glucose metabolism progressively decreases in several
distinct brain regions (299, 300). E4 individuals, however, show a state of glucose
hypometabolism in these same regions even in the absence of cognitive impairment, and
as early as the third decade of life (3). LDs are known to increase in cerebral density with
age and are found in GFAP+ cells (175). E4 carriers show an accelerated development of
AD neuropathology and cognitive symptoms, and astrocytes have been shown to play a
key role in E4-driven AD pathogenesis (301). Perhaps this accelerated AD phenotype in
E4 individuals extends to cerebral LD accumulation as well.
It has been proposed that E4 carriers may be at risk for cognitive decline because of
an E4-driven disruption in FA metabolism (302, 303). Here we showed that APOE
regulates fatty acid metabolism in the astrocyte depending on the saturation status of the
fatty acid. We observed marked decrease in uptake of the fully saturated fatty acid
palmitate in E4 astrocytes compared to E3 astrocytes while no difference was observed in
oleate uptake. When we treated with etomoxir, we saw drastic reduction in oleate oxidation
in both genotypes, but much less of a reduction in oxidation in E3 astrocyte palmitate
oxidation compared to E4. These data may shed light on a phenomenon seen in
epidemiological studies where E4 carriers respond well to an acute high fat meal (by
cognitive measures and plasma AD biomarkers), while non-E4 carriers responded poorly
(10). This may be due to a lower uptake of saturated fatty acids. Conversely, E4 carriers
have been shown to exhibit increased uptake of unsaturated fatty acids, specifically
docosahexaenoic acid (304). This could be related to the preventative effect of a Nordic
diet rich in fish, fruits, and vegetables on cognitive decline in E4 individuals (23). Indeed,
apoE isoform specific effects on lipid usage have been characterized systemically, wherein
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E4 mice show a metabolic preference for oxidizing FAs (111). Related FA disturbances
have been characterized in humans carrying E4. For instance, E4 carriers show greater
uptake, brain incorporation, and whole-body β-oxidation of docosahexaenoic acid
compared to non-E4 carriers (28, 304). In the current study, our data using 14C-labeled FAs
support the idea that E4 alters the flux of metabolites into the TCA cycle and because of
this, decreases CO2 production and increases metabolites that are acid soluble. Our group
previously showed that E4 alters numerous pathways within the cerebral metabolome (51),
and others have shown changes in TCA specific metabolites in the brain (305).

4.5

Conclusion
In this study we showed that E4 astrocytes display an increase in LD formation

compared to E3 astrocytes. Specifically, E4 astrocytes have a higher number of smaller LD
and increased expression of the LD marker PLIN2. We also observed increased oxygen
consumption rates from endogenous fatty acid oxidation, decreased rates of exogenous
fatty acid oxidation, and an increased sensitivity to CPT-1 inhibition in E4, compared to
E3, astrocytes. While a number of important questions remain, we hope these initial
findings will serve as a basis for the further study of APOE-associated alterations in
astrocyte metabolism and future treatments of AD and other neurodegenerative diseases.
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Figure 4.1 E4 astrocytes have increased lipid droplet (LD) count, LD volume, and LD
associated protein.
(A) Astrocytes expressing either E3 or E4 were stained with LipidSpot to quantify lipid
content under control conditions (left), and after 24 h oleic acid (OA) supplementation
(“lipid-loaded”; right). The number of LDs per individual cell (B) and total LD volume per
cell (C) were quantified. Values represented are means +/− SEM (n = 10). Data were
analyzed by t-test for specific comparisons between means; * p <0.05. (D) Representiative
image of the total expression of perilipin-2 (PLIN2) and β-actin in control or lipid-loaded
E3 and E4 astrocytes was determined by SDS-PAGE and Western blotting and quantified
(E). Values represent mean +/− SEM (n = 3). Data were analyzed by by t-test; * p <0.05.
Scale bar = 100µm.
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Figure 4.2 E4 astrocytes have smaller lipid droplets.
(A) Representative 3D renderings of E3 and E4 astrocytes stained with LipidSpot and
DAPI under control and lipid-loaded conditions. (B) Individual lipid droplet (LD) volume
was quantified under control and lipid-loaded conditions. Values represented are means
+/− SEM. Data were analyzed by unpaired t-test; *** p <0.001, * p <0.05. (C) Relative
frequencies of LD volumes were binned between 0 and 1 µm3 under control and (D) lipid
loaded conditions. Bin size = 0.1 µm3. E3 control LDs (n = 131); E4 control LDs (n = 775);
E3 OA LDs (n = 231); E4 OA LDs (n = 1208).
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Figure 4.3 E4 astrocytes uptake less palmitate, but not oleate.
E3 and E4 astrocytes were treated with 0.5 µCi/mL [1-14C] palmitate (A,B) or (C) [1-14C]
oleate (C,D) and uptake was measured over 150 min by a scintillation proximity assay.
Values represent mean +/− SEM (n = 6). Data were analyzed by two-way ANOVA of
repeated measures (A,C) or t-test (B,D); * p <0.05. Total area under the curve (AUC) was
determined for palmitate (B) and oleate (D).
.
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Figure 4.4 E4 astrocytes oxidize less exogenously supplied fatty acids.
(A) Schematic and summary of pulse experiment to determine oxidation of exogenously
supplied fatty acids. (B) E3 and E4 astrocytes were treated with [1-14C] oleate (OA) or [114C] palmitate (PA) and oxidation was measured over 3 h by a CO 2 trap assay. Acid soluble
metabolites were quantified in media (C) and intracellular (D) fractions. Values represent
mean +/− SEM (n = 6). Data were analyzed by t-test;*** p < 0.001, **** p < 0.0001. (E)
E3 and E4 astrocytes were pretreated for 1 h with palmitate and subjected to a Seahorse
Extracellular Flux Fatty Acid Oxidation Assay. Vertical gray dashes indicate time points
of pharmacological injections of etomoxir (Eto), oligomycin (Oligo), or Rotenone and
Antimycin (RA). (F) Oxygen consumption due to FA oxidation of exogenously supplied
palmitate was determined (see methods) and graphed. Values represent means +/− SEM (n
= 3–4). Data were analyzed by unpaired t-test; * p < 0.05.
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Figure 4.5 E4 astrocytes oxidize more endogenous fatty acids.
(A) Schematic and time-course of pulse-chase experiment to determine oxidation of
endogenous fatty acids.. (B) E3 and E4 astrocytes were treated with 1 µCi/mL [1-14C]
oleate (OA) or [1-14C] palmitate (PA) combined with non-labelled isotopes to 200 µM in
Advanced DMEM for 24 h, washed with PBS, and then oxidation was measured over 4 h
in a nutrient depleted media by a CO2 trap assay. Acid soluble metabolites were quantified
in media (C) and intracellular (D) fractions. Values represent mean +/− SEM (n = 6). Data
were analyzed by t-test; ** p < 0.01, *** p < 0.001; **** p < 0.0001. (E) E3 and E4
astrocytes were pretreated for 1 h with bovine serum albumin supplemented media and
subjected to a Seahorse Extracellular Flux Fatty Acid Oxidation Assay. Vertical gray
dashes indicate time points of pharmacological injections of etomoxir (Eto), oligomycin
(Oligo), or Rotenone and Antimycin (RA). (F) Oxygen consumption due to intracellular
FA oxidation was determined (see methods) Results were normalized to protein content.
Values represent means +/− SEM (n = 3–4). Data were analyzed by unpaired t-test; *** p
< 0.0005.
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Figure 4.6 E4 astrocytes are more sensitive to CPT-1 inhibition.
(A) Percent change in OCR for E3 and E4 astrocytes pretreated with BSA or palmitateBSA. Data represent mean of replicate wells +/− SEM (n = 3–4). Data were analyzed by
two-way ANOVA, repeated measures; **** p <0.0001. (B) Fold change in oxidation of
oleate (OA) or (PA) due to carnitine palmitoyltransferase 1 (CPT-1) inhibition was
determined by CO2 trap assays and represented as mean of replicate wells +/− SEM (OA:
n = 4; PA: n = 3). Data were analyzed by t-test; **** p <0.0001.
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CHAPTER 5. DISCUSSION AND EXPERT OPINION
5.1

Summary of dissertation
This dissertation work leverages human data, humanized mice models, and cutting

edge in vitro assays of metabolism to detail a role for the gene APOE as a metabolic
regulator at the cellular and organismal level. APOE has been studied extensively in the
context of neurodegeneration and neuropathology, peripheral lipid transport, and
cardiovascular disease (306). Here, APOE genotype is revealed to glucose flux through
central carbon pathways in astrocytes, manifesting at the systemic level by decreasing
energy expenditure in E4 carriers – a phenomenon which can be measured via indirect
calorimetry. Furthermore, a role for APOE in lipid droplet formation and utilization is
detailed in astrocytes. The literature and field of APOE metabolism regulation in the brain
and beyond is growing, and this body of work contributes substantially to our budding
understanding of this crucial gene.

5.2

APOE in human health
The polymorphic APOE gene encodes for three alleles in humans: E2, E3, and E4

(307). E3 has the highest allelic representation in the human population with 78% of
individuals carrying at least one copy of E3. E2 represents the smallest percentage of the
population at 8%. E4 carriers constitute 14% of the global population (1). Though APOE
alleles differ by single polymorphisms at two genetic loci, the alleles confer a range of
pleiotropic phenotypes. E4 is the strongest genetic risk factor for the development of late
onset Alzheimer’s disease, while E2 offers protection and is associated with longevity (59).
The E2 allele differs from the E4 allele by two amino acids (at AA 112 and AA 158) yet
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according to recent estimates lowers the odds ratio of developing late onset Alzheimer’s
disease by nearly hundredfold (308). A step wise progression of increased risk to decreased
risk with allelic dose (E4>E3>=E2) is seen in multiple diseases of the central nervous
system including dementia with Lewy bodies, frontotemporal lobar degeneration,
Parkinson’s disease, ischemic stroke, and vascular dementia (58). Furthermore, E4
increases the risk of diseases commonly thought of as diseases of the periphery, such as
hypercholesterolemia, coronary artery disease, atherosclerosis, and metabolic syndrome
(307, 309). The range of diseases, central and peripheral, associated with APOE suggests
that APOE plays a multifaceted role in human health.

5.3

Antagonistic pleiotropy as an explanation for APOE4 population frequency
A common question regarding the genetic frequency of APOE4 is: if E4 drives so

much disease risk, how could it still be selected for evolutionarily in our population? This
is likely answered by the increase in human life expectancy across history (310). We now
live longer than ever before as humans, which may be revealing age-dependent genetic
effects which may have conferred advantages in our youth (and in ancestors with shorter
lifespans) but be pathogenic in old age. This concept is known as antagonist pleiotropy and
is supported by advantageous characteristics of young E4 carriers which are lost with age
(311, 312).
5.3.1

APOE4 as the ancestral allele

To consider APOE and its relevance to human health it is useful to phylogenetically
trace the gene’s evolution, which is now feasible based on advances in molecular genetics
and anthropology. APOE is genetically conserved across mammalian and non-mammalian
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species, reflecting an ancient entry of APOE as a component of organismal genomes (313).
Mice possess an Apoe gene with a similar amino acids at AA 112 and AA 158 as human
APOE4, yet the protein behaves functionally similar to human ApoE3 since it does not bear
the domain-interaction observed in the protein structure of ApoE4 (314). Interestingly, this
shared sequence of APOE4 between humans and lower vertebrates, including non-human
primates, gives support for the theory that APOE4 is the ancestral allele, and that the other
alleles arose from evolutionary selection (315). This is also supported by the geographical
distribution of the alleles across the continents; APOE4 has a much higher population
frequency in the indigenous populations of Central Africa (40% in Aka Pygmies, 38% in
Tutsis, 33% in Zairians, and 29% in Fon), Oceania (49% in the Hui population of New
Guinea), and Australia (26% in the Mowanjum aboriginal tribe) relative to its worldwide
frequency (316, 317). Therefore it appears that APOE4 was the original allele in our ancient
ancestors.
5.3.2

Unique human APOE polymorphisms

The polymorphic nature of APOE in humans is unique (318). No other species
known to date has multiple common alleles for the APOE gene. Therefore, if we assume
that APOE4 was the ancestral allele and evolutionary pressures gave rise to APOE3 and
APOE2, it would seem that these evolutionary pressures were unique upon the human
species. If a global event had occurred that would have selected for mutations in the APOE4
common ancestral allele, more species would likely share the polymorphic APOE as seen
in humans.
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5.3.3

Historical shift in human feeding patterns

In the course of human history it has been necessary to metabolically adapt to our
environmental energy supply apart from other species. Ancient humans likely were
stationary until resources were depleted relative to the population size, which then required
humans to compete for resources (319). With territorial disputes and large-migrations away
from resources, human metabolism was challenged to adapt due to food scarcity. Prehistoric hunter gatherers were accustomed to a “feast and then fast” dietary program and
required metabolic adaptations to fuel the body in times of starvation to adequately store
energy during times of energy availability to permit survival. Extended foraging distances
required endurance and conversion of bodily energy stores into usable energy substrates
critical to maintain energy homeostasis (320). As the body begins a period of fasting,
energy stores are tapped, releasing non-esterified fatty acids from lipolysis of triglyceride
adipose reservoirs, glucose from glycogen stores and gluconeogenesis, and amino peptides
from proteolysis. Importantly, genes that promoted energy pool tapping and utilization
would have been selected for in the gene pool during this period of human evolution.
Conversely, genes that are associated with impairments or inefficiencies in energy
utilization would likely be negatively selected. This may help explain why APOE, a gene
associated with mobilization of fatty acids for energy, is polymorphic in humans alone. It
may be that E3 and E2 conferred metabolic advantages over the E4 allele in our human
ancestors that resulted in the current population frequencies millennia later. It is also
possible that E4 was the advantageous allele for the hunter gatherer population due to its
“thrifty” nature allowing extended lipoprotein circulation and increased storage (317).
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5.3.4

Modern day feeding on the background of inherited ancestral genetics

Shifting to the present, we are now accustomed to an excess of caloric availability
and modern humans typically follow a “feast and then feast” diet. Therefore, processes of
energy management and efficiency are relatively less active in modern humans consuming
excess calories compared to our ancestors. The increase in caloric consumption and our
increased life expectancy has occurred relatively rapidly. Yet, our species carries the
genetic profile of humans in a world where energy was scarce, feeding was rare, and life
expectancy was shorter.
This drastic shift in our energy availability and consumption has occurred in
parallel with a rise in the incidence of diseases of metabolic dysfunction including type 2
diabetes, metabolic syndrome, and obesity. These diseases of metabolic dysfunction
increase the risk of dementia and share several pathological characteristics with
Alzheimer’s disease (AD), such as inflammation, increases in oxidative stress and vascular
dysfunction (321, 322). Metabolic disorders also increase in incidence with age, (323) and
a rapidly aging demographic means the number of individuals suffering from both
metabolic disorders and AD is expanding precipitously. While diet has been proven to play
a role in the rise of these diseases, the influence of diet-by-gene interactions on disease risk
is just beginning to be understood.

5.4

APOE, astrocytes, and cerebral metabolic flexibility
Normal brain function requires a multitude of energy-intensive processes, and a

complex and intricately linked interplay between neurons and supporting glia is necessary
to maintain efficient energy metabolism. Astrocytes in particular play a critical role in brain
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homeostasis, regulating both local energy metabolism and defense against oxidative stress,
two aspects of great importance to neuronal viability and function (96, 324). Being the
specialized metabolic neighbors of neurons, astrocytes bridge the distance between the
vasculature and the energetically needy synaptic parenchyma. In contrast to neurons,
astrocytes are highly glycolytic but also able to β-oxidize fatty acids (325, 326). This
unique ability of fuel switching from primarily carbohydrate metabolism to fatty acid
oxidation is vital for neuronal health in times of variable energy supply as in our ancestors’
environments. Metabolic inflexibility, that is the inability to utilize other substrates in the
context of substrate deprivation, occurs in situations of caloric oversupply as a result of
mitochondrial indecision (327). Essentially a traffic jam occurs at the key nodes of central
carbon metabolism leading to metabolic gridlock instead of normal flux and energy
production. This is detrimental in the brain where tight metabolic coupling between
astrocytes and neurons depends on cooperative and smooth metabolic networks to sustain
cerebral viability. Since astrocytes are the primary cell type in the brain to produce ApoE,
and are key suppliers of metabolites to neurons, we chose to utilize in vitro astrocyte
models to study the APOE genotype-specific alterations in fatty acid and glucose
metabolism.
5.4.1

Glucose hypometabolism as a shared feature of AD and E4 brains

E4 carriers and individuals with AD both display an underutilization of glucose as
a brain fuel source, seen early in AD disease progression and even in young and healthy
E4 carriers (4). Even non-demented, cognitively normal E4 carriers demonstrate this
pattern of glucose hypometabolism, thereby lending support to this being an inherent
biological feature of E4, rather than simply a byproduct of dementia (3). Importantly,
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glucose hypometabolism is considered the earliest detectable change in the AD brain
regardless of APOE genotype, reflecting a pre-symptomatic biomarker and potential nidus
for incipient AD (328).

5.5

Metabolic inflexibility as a unifying mechanism to explain E4-associated
antagonistic pleiotropy and disease risk
It is possible that E4 drives glucose hypometabolism due to the metabolic gridlock

associated with over consumption of energy substrates that is common in our modern era.
While E4 conferred a survival advantage in hunter gathers when resources were scarce and
energy storage was more important than energy utilization, today E4’s advantage is
overcome by the carbohydrate rich diets of Western civilization which give E4 carriers an
energy surplus that they are not adapted for. This metabolic indecision would occur at the
level of the mitochondria, leading to overall decreases in ATP production, fuel oxidation,
and glucose uptake due to negative feedback mechanisms.
E4 as a driver of metabolic inflexibility would explain why in chapter 2 we
observed increased lactate production in human, mice, and astrocytes fed glucose since the
glucose is fluxed through aerobic glycolysis rather than the high energy yielding oxidative
phosphorylation. We observed that deficits in oxidation and energy expenditure at baseline
were exacerbated after a glucose challenge, implying that energy substrate supply (at least
in terms of carbohydrates) worsens the E4 effect on metabolism. Previous work by our
group demonstrated that mice fed a high fat diet also show exacerbated glucose metabolic
impairments and worsened outcomes of cognition (43). Lactate has been shown to
compete with glucose for uptake and oxidation, as shown in chapter 2. Therefore,
metabolic inflexibility is doubly problematic since energy oversupply leads to suppressed
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glucose oxidation resulting in increased lactate which then also acts to impair glucose
oxidation.
Mitochondrial inflexibility would also explain why when we inhibited glutamine
metabolism and fatty acid oxidation in E4 astrocytes, they were significantly less flexible
at upregulating glucose oxidation relative to E3 astrocytes. It is important to note, however,
that the energy substrates (glucose, fatty acids, glutamine) were all present during this
experiment, and only pharmacological inhibitors were used to shut down metabolic
pathways. This is distinct from a true “starvation” environment in which energy substrates
would be absent.
Regarding chapter 4, the E4 astrocytes were shown to increase storage of LDs and
increase oxidation of the LD pools, but only when they were starved of glucose. That is,
only when we removed the nutrient-dense media did we observe an increase in fatty acid
oxidation from the LD pool over in E4 astrocytes relative to E3 astrocytes. This is
consistent with the ‘thrifty’ gene hypothesis since E4 astrocytes showed an advantage in
times of nutrient scarcity, and were shown to increase storage of energy substrates in times
of nutrient abundance.
Regarding chapter 1, many dietary interventions have been tried in E4 carriers with
minimal success. Perhaps the repeated failures of dietary interventions can be explained by
the nature of the dietary interventions, that is, the E4 carriers were still consuming an
abundance of calories regardless of the type of diet. Dieting may not be the answer to
mitigating E4 risk. Instead, I would advocate for a feeding regimen similar to our human
ancestors. A diet with restricted feeding and intermittent fasting. To date, there has been
no evidence based clinical study showing a beneficial (or non-beneficial) effect of
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intermittent fasting in E4 carriers. However, a recent case report of a ketogenic diet
intervention in a morbidly obese 68 year old male E4 carrier with mild AD and type 2
diabetes showed promise (329). The patient was screened at baseline via the Montreal
Cognitive Assessment (MoCA) test and comprehensive diabetic and lipid tests. The patient
was prescribed a ketogenic diet over a 10-week period with intermittent fasting on an 8
hour time-restricted feeding window for 3 days per week. The patient showed remarkable
improvement from baseline in HgA1c levels (from diabetic to normal range), fasting
insulin (85% reduction), body weight (5.5% reduction), and HDL levels (35.7%
improvement). Furthermore, MoCA revealed an improvement in cognition with the patient
scoring in the mild-AD range at baseline (23/30) and normative range post-intervention
(29/30). While this is only a case report (n=1), the study begs the question; are the
metabolic derangements driven by E4 mitigated by simply restricting feeding? Future
studies are needed in APOE mice models and humans to address this fundamental gap in
our knowledge.
The metabolism hypothesis of AD states that the primary pathogenic driver of
disease progression is altered brain metabolism (330). This hypothesis is supported by a
number of studies that reflect AD-associated impairments in mitochondrial respiration and
aberrant upregulation of glycolysis. For example, fibroblasts taken from LOAD patients
show inherent decreased glucose oxidation, diminished mitochondrial membrane potential,
increased oxidative stress, and a Warburg-type effect that is unrelated to the age of the
patient (331, 332). Recent proteomic profiling of over 2000 AD brain samples revealed
that changes in expression of proteins involved in glial metabolism is the most significant
module associated with AD pathology and cognitive decline (118). Increased expression
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of enzymes in this module included lactate dehydrogenase, pyruvate kinase, and
glyceraldehyde-3-phosphate dehydrogenase, all of which are elevated in aerobic
glycolysis/Warburg phenotypes. Laser microdissection of neurons from the posterior
cingulate of AD postmortem samples has revealed reduced expression of electron transport
genes (333). AD-related reduction in ETC activity may also explain findings from Terada
and colleagues who used a novel FDG probe that binds to mitochondrial complex 1 to show
oxidative metabolic failure in parahippocampal regions of living early stage AD brains
(334). As stated previously, AD brains show lower FDG PET uptake and this is considered
one of the earliest biomarkers of disease (328, 335). FDG-PET is able to differentiate AD
from other types of dementia with a high degree of specificity due to specific regional
signaling patterns.(336) Detectable AD symptoms essentially never occur without lower
FDG-PET signal, and the degree of FDG-PET signal loss is strongly correlated with the
severity of clinical symptoms (337-339). Interestingly, analysis of CSF samples from 32
confirmed AD patients showed a significant correlation between increased CSF lactate and
reduced glucose uptake (by FDG PET) in parahippocampal areas, the medial prefrontal
cortex, and the left orbitofrontal cortex. Imaging studies in live AD patients via magnetic
resonance spectroscopy have shown elevated lactate levels in the posterior
cingulate/precuneus region compared to controls (340). Elevated brain lactate correlates
strongly with mild cognitive impairment progression (341), and in a mouse model of AD
correlates well with interstitial amyloid beta levels.
Based on the data shown in this dissertation, I believe that E4 may be a causative
driver of AD based on its effect on metabolic flexibility and subsequent lactate production.
Specifically, I hypothesize that E4 carriers consuming high-caloric diets have greater risk
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for developing AD because of the increased flux of glucose through aerobic glycolysis to
lactate. This lactate then serves to suppress glucose uptake in the brain and drive traditional
AD pathology through mechanisms yet to be determined.

5.6

Future studies
Discovering early biological signs that forecast future disease is critical in primary

prevention of disease. With the elderly population predicted to increase significantly in the
coming decades, early detection and intervention will be critical to lower healthcare burden
in the treatment and care of AD patients. Young female E4 carriers offer a unique sample
population as being at high risk for development of late onset AD, yet with no age-related
AD symptomology. Similar to the seminal finding that young E4 carriers show FDG-PET
imaging congruent with AD patients (3), we show here that young female E4 carriers show
a resting energy expenditure profile congruent with aged individuals. It is unclear if whole
body energy expenditure is altered in AD (342) and future studies aiming to validate
indirect calorimetry as a screen for AD risk should confirm EE alterations in the AD
population.

5.7

Conclusion
In summary, I have shown that APOE regulates fatty acid metabolism in astrocytes,

whole body response to glucose challenges in humans and mice, and central carbon
pathways in mice brains and astrocytes. These data show the metabolic effects of E4 in the
central nervous system but also show peripheral mechanisms for APOE regulation of
metabolism. While questions remain, these findings inform the field of neurometabolism
and shed light on how the E4 allele contributes to AD risk.
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APPENDICES

5.8

APPENDIX 1 – CHAPTER 2 SUPPLEMENTARY MATERIALS

Supplementary Table 1 – Ratios of plasma metabolite abundances in human participants
with or without the E4 allele.
(all comparisons shown are E4+ vs E4-)

Pre-glucose
challenge

Post-glucose
challenge

Metabolite

HMDB ID

Ratio

FDR

Ratio

FDR

beta-alanine

HMDB0000056

1.059

0.797

1.179

0.314

cholesterol

HMDB0000067

1.176

0.541

1.084

0.699

citrate

HMDB0000094

1.258

0.273

1.276

0.152

GABA

HMDB0000112

1.203

0.532

1.419

0.096

glyoxylic acid

HMDB0000119

0.822

0.489

0.891

0.542

glycine

HMDB0000123

1.102

0.717

1.098

0.546

glycerol 3-phosphate

HMDB0000126

1.002

0.994

0.853

0.542

fumaric acid

HMDB0000134

0.940

0.797

0.822

0.314

glyceric acid

HMDB0000139

1.243

0.193

1.310

0.034

glutamic acid

HMDB0000148

1.427

0.066

1.757

0.011

ethanolamine

HMDB0000149

1.141

0.532

1.160

0.291

tyrosine

HMDB0000158

1.072

0.797

1.331

0.153

phenylalanine

HMDB0000159

0.999

0.994

1.141

0.354

maltose

HMDB0000163

1.143

0.775

1.681

0.028

threonine

HMDB0000167

0.597

0.107

0.897

0.546

isoleucine

HMDB0000172

1.063

0.798

1.183

0.299

lysine

HMDB0000182

0.929

0.797

1.197

0.216

lactose

HMDB0000186

1.218

0.466

1.471

0.057
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serine

HMDB0000187

1.025

0.919

1.277

0.118

lactate

HMDB0000190

1.519

0.001

1.264

0.013

oleic acid

HMDB0000207

0.722

0.294

0.991

0.957

α-ketoglutarate

HMDB0000208

1.084

0.775

1.057

0.715

myo-inositol

HMDB0000211

1.149

0.532

1.508

0.028

n-acetylgalactosamine

HMDB0000212

1.507

0.054

1.359

0.275

palmitic acid (polar lipids)

HMDB0000220

1.074

0.797

1.341

0.098

n-acetyl-neuraminic acid

HMDB0000230

1.026

0.919

1.676

0.013

pyruvate

HMDB0000243

1.128

0.532

1.108

0.464

sucrose

HMDB0000258

0.817

0.649

0.791

0.326

serotonin

HMDB0000259

0.757

0.242

1.032

0.861

pyroglutamic acid

HMDB0000267

1.256

0.312

1.336

0.153

ribose

HMDB0000283

0.9659

0.894

1.102

0.546

urea

HMDB0000294

1.1415

0.621

1.117

0.441

creatinine

HMDB0000562

0.7535

0.445

0.701

0.098

fructose

HMDB0000660

1.212

0.489

1.429

0.028

linoleic acid polar

HMDB0000673

0.914

0.797

1.066

0.750

methionine

HMDB0000696

1.268

0.358

1.205

0.313

homoserine

HMDB0000719

0.857

0.647

0.688

0.098

malic acid

HMDB0000744

1.185

0.441

1.185

0.247

3-phosphoglyceric acid

HMDB0000807

1.306

0.0843

1.398

0.018

stearic acid

HMDB0000827

1.156

0.532

1.317

0.143

valine

HMDB0000883

1.174

0.533

1.217

0.284

tryptophan

HMDB0000929

0.957

0.822

1.105

0.54

threonic acid

HMDB0000943

1.464

0.065

1.977

0.0013

F16BP

HMDB0001058

0.783

0.242

0.927

0.584

glucosamine-1-phosphate

HMDB0001109

0.739

0.193

0.883

0.527
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alanine

HMDB0001310

1.018

0.919

1.192

0.244

guanosine-5-phosphate

HMDB0001397

1.063

0.797

0.848

0.353

glucosamine

HMDB0001514

1.531

0.066

1.724

0.002

oxalic acid

HMDB0002329

1.024

0.919

0.929

0.715

threose

HMDB0002649

0.772

0.414

1.043

0.772

n-acetyl-tryptophan

HMDB0013713

1.076

0.797

1.220

0.354

acetohydroxamic acid

HMDB0014691

1.186

0.532

1.187

0.353

aspartyl-glutamate

HMDB0028752

0.581

0.162

0.576

0.096

leucine

HMDB00687

1.077

0.797

1.265

0.152
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Supplementary Table 2. Pre-screening checklist. A response of “yes” to any of the
following resulted in exclusion from the study.

Pre-Existing Symptoms Checklist

INSTRUCTIONS: Review this list at each
visit. If any symptom is present at Baseline,
be sure to report it on the on medical
history

Symptom

Yes

No

1. pregnant or breastfeeding

Yes

No

2. have a bleeding disorder
3. allergy to the local anesthetic lidocaine

Yes
Yes

No
No

4. history of stroke, seizures, Parkinson’s
disease, history of head injury with loss of
consciousness, or other dementing disorder

Yes

No

5. history of alcoholism or drug abuse

Yes

No

6. History of schizophrenia or currently
suffer from bipolar disorder or major
depression.
7. vision or hearing loss severe enough to
interfere with cognitive testing

Yes

No

Yes

No

8. Taking Beta Blockers (ex. Sectral,
Tenormin, Zebeta, Lopressor, Corgard,
Bystolic, Inderal LA, InnoPran XL)

Yes

No

9. Taking Neuroleptics (ex. Clozaril,
Saphris, Zeprexa, Seroquel)

Yes

No

10. Taking Narcotic Analgesics (ex.
Codeine, Zohydro ER, Oxycodone,
Methadone, Hydromorphone, Morphine,
Fentanyl)

Yes

No

11. Taking Anti-Parkinsonian Agents (ex.
Sinemet, Symmetrel, Artane, Cogentin,
Elderpryl, Azliect, Comtan)

Yes

No

12. Taking CNS-Active antihypertensive
agents (ex. Catapres, Kapvay, Intuniv,
Tenex)

Yes

No

Information obtained by:
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Comments

Fig. S1. Human indirect calorimetry study design
(A) Representative time course of energy expenditure (EE) measures during the three
periods of the study (rest in gray, cognitive challenge in green, and glucose challenge in
orange). Data was only analyzed during the last 25 minutes of the resting and glucose
periods and during a common 5-15 minute span during the cognitive challenge in which
all 100 subjects were actively engaged in the task – denoted by grey bar on x axis. Blood
was drawn immediately prior and after the glucose challenge. (B) Representative photo
of a participant during the resting challenge connected to the Ultima MGX indirect
calorimetry (IC) system. (C) Example slides from the Novel Image Novel Location test
used as a cognitive challenge. (D) The glucose challenge consisted of a blood draw,
followed by ingestion of the 50g sugar drink (all subjects consumed drink within 90
seconds), followed by IC measurement, and a second blood draw.
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Fig. S2. Respiratory Exchange Ratio (RER) does not differ by APOE genotype.
Respiratory exchange ratio (RER) (VCO2/VO2) was not significantly different
between APOE genotypes across any of the three periods tested.
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Fig. S3. E4 effect on resting energy expenditure
(A) E4 non-carriers’ (blue) and E4 carriers’ (purple) average resting energy expenditures
were determined and stratified by young and middle-aged. (*P<0.05, ***P<0.001,
unpaired t-test, two-tailed)(B) This was repeated for only male participants (*P<0.05,
unpaired t-test, two-tailed). (C) Average EE was plotted over the resting period for
females and (D) males. Dotted lines indicate liner regression results and shaded area are
SEMs.
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Fig. S4. Novel image novel location object recognition test response accuracy by
APOE genotype.
(A) The novel-image-novel-location (NINL) object recognition test contains 7 sets of
12 slides. Each slide has 3 images and 4 possible locations. Each slide is viewed for
eight seconds in the order as follows: See Set A, See Set B. Test Set A, See Set C, Test
Set B, See Set D, Test Set C, etc. To be considered correct, subjects must identify both
the type of change and in which quadrant the change has occurred. The test is designed
so that on average subjects answer 60-80% of questions correctly. Total percent correct
was calculated for each genotype (B) and stratified by E4 carriage. (C) Individual slopes
of EE after the cognitive challenge showing an average decrease in EE after the
challenge.
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Fig. S5. E4 effect on energy expenditure during glucose challenge

(A) Energy expenditure (B) VCO2 and (C) VO2 was plotted over the glucose challenge
period in all E4- (blue) and E4+ (purple) participants. (*P<0.05, Two-way ANOVA
repeated measures). (D) Thermic effect of feeding was determined as a ratio of E4 noncarriers in all, young, and middle-aged participants. (**P<0.01, unpaired t-test, twotailed) (E) Energy expenditure (F) VCO2 and (G) VO2 was plotted over the glucose
challenge period in male participants. Dotted lines show linear regression trend line,
shaded areas refer to SEM. (H) Thermic effect of feeding was determined as a ratio of
E4 non-carriers in all, young, and middle-aged male participants.
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Fig. S6. Plasma lactate assessed via enzymatic assay.
(A) Lactate values quantified by GCMS (relative abundance, y-axis) strongly correlate
with lactate values (uM) assessed via enzymatic assay. (B) E4 carriers had higher plasma
lactate pre-drink and a trend toward higher lactate post-drink (p=0.09) compared to noncarriers, as measured via enzymatic assay.
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Fig. S7. Activity, food consumption, and age comparisons from mice indirect
calorimetry
(A) Activity and (B) food consumption during light cycles were averaged for E3 and
E4 mice. (C) Analysis of covariance was performed by separately correlating average
EE and body weight for E3 and E4 mice. (Spearman correlation r=0.86, ***P<0.001).
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Fig S8. Indirect calorimetry data from male mice
(A) Normal chow and (B) high carbohydrate data from male mice only corresponding
to Fig 4.
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Fig S9. Indirect calorimetry data from female mice
(A) Normal chow and (B) high carbohydrate data from female mice only corresponding
to Fig 4.
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Supplementary Materials and Methods
Glucose metabolism assays
For glucose oxidation assays, astrocytes were plated in a 24-well plate at 300,000
cells/well with 500 µL of maintenance media (Advanced DMEM, 10% FBS, 1% sodium
pyruvate, 0.4% Geneticin) and incubated at 5% CO2 and 37°C and allowed to grow to
confluency for 24 hours. Using a previously published protocol (290), cells were then
incubated with 1 µCi/mL [U-14C] glucose in maintenance media (25mM glucose) or
starvation media (same as maintenance except 0mM glucose) for 3 hours. Buffered 14CO2
in the media was then liberated by addition of 1 M perchloric acid and captured on a filter
paper disc pre-soaked with 1N sodium hydroxide using airtight acidification vials.
Radioactivity of the filter paper was measured in a Microbeta 2 Scintillation Counter
(Perkin Elmer) after addition of 3 mL Ultima-Gold Scintillation Fluid.
For glucose tracing in primary astrocytes, cells were plated in a 6-well plate at
600,000 cell/well in astrocyte growth media (Advanced DMEM, 10% FBS, 1% sodium
pyruvate, 1% penicillin-streptomycin) and incubated at 5% CO2 and 37°C. After 48 hours,
growth media was replaced with tracer media (Glucose-free DMEM containing 10%
dialyzed FBS, 10mM [U-13C] glucose) and incubated under previous conditions for 24
hours at which time quenching and metabolite extraction were carried out as follows: Plates
were retrieved from incubator and placed on ice, tracer media removed and wells washed
once with ice-cold PBS. Immediately following washing, 1 mL of ice-cold extraction
buffer (50% MeOH, 20nM norvaline) was added to quench enzymatic activity and plates
were placed at -20°C for 10 min. Cellular contents were then scraped with a cell-scraper in
extraction buffer and collected into 1.5 mL and tubes placed on ice for 20 min with regular
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vortexing. Samples were then centrifuged at 14,000 rpm, 10 min, 4°C after which
supernatant containing polar metabolites were removed to a new tube and frozen at -80°C
until prepped for GCMS analysis. The resulting pellet was re-suspended in RIPA buffer
(Sigma) and protein concentration was measured with BCA kit (Pierce) for normalization.

Glucose tracing in vivo
Female TR mice homozygous for E3 or Ε4 (12-13 mo) were fasted for 2-3 hours
then, via oral gavage, administered 250 uL [U-13C] glucose solution at a concentration of
2 g/kg of body weight based on average cohort bodyweight. 45 minutes following gavage,
mice were euthanized by cervical dislocation, brains were removed and quickly washed
twice in PBS, once in H2O then frozen in liquid N2. Tissues were kept at -80°C until ground
under liquid N2 using a Freezer/Mill Cryogenic Grinder (SPEX SamplePrep model
9875D). Approximately 60 mg of tissue was placed in a 1.5 mL tube then 1 mL extraction
buffer (50% MeOH, 20nM norvaline) was added followed by a brief vortex and placed on
ice for 20 min, briefly vortexed every 5 min. Samples were then centrifuged at 14,000 rpm,
4°C for 10 min. The supernatant containing polar metabolites was removed to a new tube
and kept at -80°C until prepped for GCMS. The resulting pellet was re-suspended in RIPA
buffer (Sigma) and protein concentration was measured with BCA kit (Pierce) for
normalization.

GCMS Sample Preparation
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Polar metabolites were thawed on ice then dried under vacuum. Dried pellet
dissolved in 50 uL methoxyamine HCl-pyridine (20 mg/ml) solution and heated 60 minutes
at 60°C. Following heating, samples were transferred to v-shaped glass chromatography
vials and 80 ul of MTSFA + 1% TMCS (Thermo Scientific) was added. Samples then
heated for 60 minutes at 60°C then allowed to cool to room temperature and analyzed via
GCMS with parameters as previously described (343). Briefly, a GC temperature gradient
of 130°C was held for 4 minutes, rising at 6°C/min to 243°C, rising at 60°C/min to 280°C
and held for two minutes. Electron ionization energy was set to 70 eV. Scan and full scan
mode used for metabolite analysis, spectra were translated to relative abundance using the
Automated Mass Spectral Deconvolution and Identification System (AMDIS) software
with retention time and fragmentation pattern matched to FiehnLib library with a
confidence score of >80. Chromatograms were quantified using Data Extraction for Stable
Isotope-labelled metabolites (DExSI) with a primary ion and two or more matching
qualifying ions. Metabolite quantification was normalized to relative abundance of internal
standard (L-norvaline), brain and cell data also normalized to protein concentration.
Metabolomics data was analyzed using the web-based data processing tool Metaboanalyst
(344). Metabolites significantly altered by APOE genotype and/or time point were defined
by ANOVA and subsequent false discovery rate cutoff of < 0.05. All identified metabolites
for which >75% of participants had a measurable concentration were included, and missing
values were estimated with an optimized random forest method (345). For the pathway
impact analysis, the parameters were set to ‘global test’ and ‘Relative-betweenness
Centrality’, a node centrality measure which reflects metabolic pathway ‘hub’ importance.
For enrichment analyses, parameters were set to “Pathway-associated metabolite sets
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(SMPDB)”, a library that contains 99 metabolite sets based on normal human metabolism.
For both pathway and impact analyses, only metabolic pathways with 3+ metabolites
represented in our data set were included, and a false discovery rate cutoff of <0.05 was
utilized.

Mitochondrial respiration assays
Astrocytes were plated at 40,000 cells/well in maintenance media and grown to
confluency for 24 hours. The following day media was replaced with assay running media
(Seahorse XF Base Medium, 1mM pyruvate, 2mM glutamine, and 10mM glucose) and
after 1 hour oxygen Consumption rate (OCR) and extracellular acidification rate (ECAR)
were measured using a Seahorse 96XF instrument as previously described
(126). Manufacturer protocols were followed for the glycolysis stress test assay and Mito
fuel flex assay. Briefly, the glycolysis stress test assesses the ability of cells to respond to
challenging conditions by increase the rate of glycolytic activity. Glycolytic capacity refers
to the glycolytic response to energetic demand from stress (Glycolytic capacity = ECAR
post-oligomycin – Baseline ECAR) while glycolytic reserve refers to the capacity available
to utilize glycolysis beyond the basal rate (Glycolytic reserve = ECAR post-oligomycin –
ECAR post-glucose). The Mito Fuel Flex assay assesses mitochondrial energy
consumption by measuring respiration in the presence or absence of fuel pathway
inhibitors. The following equations were used in the calculations of mitochondrial
flexibility parameters: Dependency (%) = [(Baseline OCR - Target inhibitor OCR)/
(Baseline OCR - All inhibitors of OCR)] x 100%. Capacity (%) = 1 / [(Baseline OCR -
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Other two inhibitors of OCR)/(Baseline OCR - All inhibitors of OCR)] x 100%. Flexibility
(%) = Capacity (%) - Dependency (%).
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5.9

APPENDIX 2 – CHAPTER 4 SUPPLEMENTARY MATERIALS

Supplementary Figure 1 - E4 astrocytes express more perilipin-2
E3 and E4 astrocytes were incubated in Advanced DMEM with or without 250 µM oleic
acid (OA) conjugated to BSA. Protein was extracted by RIPA lysis and 20µg was loaded
for immunoblot analysis of perilipin-2 (PLIN2 with β-actin as a loading control.
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Supplementary Figure 2 - E4 astrocytes secrete less ApoE into the media and have less
intracellular ApoE
(A) Media and cell lysates from E3 and E4 astrocyte cell cultures were isolated. Samples
were assayed for ApoE using Abcam Human ApoE ELISA kit as previously described
(346). (B) E3 and E4 cell lysates were separated using SDS-PAGE and immunoblotted
for total human ApoE and β-actin as loading control.

123

Supplementary Figure 3 – E4 astrocytes form more lipid droplets
(A) E3 and E4 expressing astrocytes were lipid loaded for 24 hours in control or oleic acid
supplemented media. Cells were fixed and incubated with oil red O to stain lipid droplets.
(B) Oil red O stained LDs were quantified using image J. Values represent means +/- SEM
from 8 images. Data was analyzed by t-test. **p<0.005
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Supplementary Methods

Oil Red O Histology
Oil Red O staining was performed as previously described (346). Astrocytes were plated
on TissueTek chamber slides. After lipid incubation, media was aspirated and slides were
washed 2X with sterile PBS. 4% PFA was added for 30 min at 37 C to fix the cells,
followed by a PBS wash. 60% isopropanol was added to the chamber wells for 5 min for
permeabilization. Isopropanol was aspirated and the cells were dried. Oil red O was then
added to the chamber wells for 20 min followed by 3 washes in ddH2O. Chambers were
removed from the slides and then coverslips were mounted. Images were acquired at 100X
on a phase contrast Nikon microscope under oil immersion.
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Kluemper, J., Farmer, B. C., Johnson, L.A. The effects of oxidative stress on lipid droplet
formation in APOE expressing astrocytes. UK College of Medicine 2019 Physiology
Research and Education Day. 5/22/2019

Khanal R, Nation GK, Farmer BC, Williams HC, Carter DJ, Brandon JA and Johnson
LA. Using Plasma and Breath Measures to Detect APOE-dependent Changes in
Metabolism. Undergraduate Research Showcase. Lexington, KY. 4/24/19

Khanal R, Nation GK, Farmer BC, Williams HC, Carter DJ, Brandon JA and Johnson
LA. Using Plasma and Breath Measures to Detect APOE-dependent Changes in
Metabolism. UK Center for Clinical and Translational Science Conference. Lexington,
KY, 4/15/19.
Kluemper J, Farmer BC, Johnson LA. The effects of oxidative stress on lipid droplet
formation in APOE expressing astrocytes. UK Center for Clinical and Translational
Science Conference. Lexington, KY, 4/15/2019
*Farmer BC. Apolipoprotein E4 Alters Astrocyte Fatty Acid Metabolism and Lipid
Droplet Formation. University of Kenutcky CCTS 2019 Annual Conference. Lexington,
KY 4/15/19
*selected for oral presentation
Farmer BC. Apolipoprotein E4 Increases Lipid Droplet Formation in Astrocytes. UK
Department of Physiology Seminar. Lexington, KY, 3/27/19
*Farmer BC. Disovering APOE’s Metabolic Role in Humans, Mice, and Astrocytes.
WKU Department of Biology Seminar. Bowling Green, KY 2/15/19
*invited speaker
*Farmer BC, Kluemper JC, Johnson LA. Apolipoprotein E Isoforms Modulate Astrocytic
Lipid Metabolism. Southeastern Regional Lipid Conference. Cashiers, NC, 11/8/18
*selected for oral presentation
*selected for travel award
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*Farmer BC, Carter DJ, Nation GK, Khanal R, Johnson LA. APOE Genotype Effect on
Respiratory Quotient – A Potential Biomarker for Alzheimer’s Disease Risk. 2018
Neuroscience Clinical-Translational Research Symposium, Kentucky Neuroscience
Institute, 10/5/18
*selected for oral presentation
Khanal R, Farmer BC, Brandon JA, Carter DJ, Kluemper J, Johnson LA. APOE and Fatty
Acid Metabolism: E4 Increases Astrocyte Lipid Droplet Formation. Cardiovascular
Research Day, University of Kentucky, 9/21/18
*Brandon JA, Farmer BC, Carter DJ, Williams HC, Khanal R, Kluemper J, Johnson LA.
APOE and Energy Substrate Balance: E2 Promotes Glucose Uptake and Utilization in
Astrocytes. Neurobiology of Brain Disorders, Gordon Research Conference, Barcelona,
Spain, 8/6/18
* selected for oral presentation
*Farmer BC. “60-second Blitz”. Apolipoprotein E ɛ4 Promotes Lipid Droplet Formation
in Astrocytes. UK Dept of Physiology Research Retreat. Lexington, KY. May 16, 2018.
*competition awardee
Farmer BC, Kluemper J, Williams HC, Fields L, Carter DJ, Brandon JA, Johnson L.
Apolipoprotein E ɛ4 Promotes Lipid Droplet Formation in Astrocytes. UK Dept of
Physiology Research Retreat. Lexington, KY. May 16, 2018.
Carter DJ, Farmer BC, Brandon JA, Johnson LA. APOE Metabolism and Cognitive
Function: An Assessment via Indirect Calorimetry. American Physician Scientists
Association, Chicago, IL, 4/21/18
Farmer BC. APOE Metabolism and Cognitive Function: An Assessment via Indirect
Calorimetry. “60-Second Pitch”, UK 13th Annual CCTS Spring Conference, Lexington,
KY, 4/13/18
Carter DJ, Farmer BC, Brandon JA, Johnson LA. APOE Metabolism and Cognitive
Function: An Assessment via Indirect Calorimetry. UK 13th Annual CCTS Spring
Conference, Lexington, KY, 4/13/18
* Farmer BC, Kluemper J, Williams HC, Fields LW, Carter DJ, Brandon JA, Johnson LA.
Apolipoprotein E ɛ4 Promotes Lipid Droplet Formation in Astrocytes. Kentucky Chapter
of the American Physiological Society, Annual Conference, University of Louisville, 2018
Apr 7
* won Best Poster Award
Williams HC, Farmer BC, Carter DJ, Brandon JA, Johnson LA. Apolipoprotein E4
Decreases Glycolysis and Reduces Glucose Uptake and Lactate Secretion in Astrocytes.
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Kentucky Chapter of the American Physiological Society, Annual Conference, University
of Louisville, 2018 Apr 7
Farmer B, Cho J, Albuquerque R. Gender Specific Inflammasome Activation in the
Trigeminal Ganglion. 2017 Annual CCTS Spring Conference. 2017 Mar 30; Lexington,
KY
Farmer, B, Beckett T, Murphy P. APP/PS1 Model for Determining the Role of AmyloidBeta Peptide in Inclusion Body Myositis. 2016 AOA Groves Memorial and MD/PhD
Program Student Research Symposium. 2016 Feb 4; Lexington, KY
Farmer, Brandon C., "Endothelin-1 Promotes Bovine Corneal Endothelial Cell
Proliferation via a MAPK Pathway: Implications for Keratopathy and Deturgescence"
(2015). College Capstone Experience/Thesis Projects. 557.
Brandon Farmer, Haichun Yang, MD/PhD, Agnes Fogo, MD.; Fibroblast-Specific
Knockdown of PAI-1 Attenuates Kidney Interstitial Fibrosis. 2014 Southeastern Medical
Scientist Symposium; 2014 Aug 23-24; Atlanta, GA
Brandon Farmer, Leah Frazier, BS, Akhila Bethi, MS.; Ken Crawford, Ph. D.;
Endothelin-1 induces phosphorylation of ERK 1/2 in bovine corneal endothelial cells. 2014
Annual Meeting of the Association for Research in Vision and Ophthalmology; 2014 May
4-8; Orlando, Fl.
Farmer B, Bethi A. Endothelin-1 Induces Phosphorylation of ERK 1/2 in Bovine Corneal
Endothelial Cells. 99th Annual Kentucky Academy of Sciences Conference. Murray, KY,9
Nov 2013.
Farmer B, Bethi A. Endothelin-1 Induces Phosphorylation of ERK 1/2 in Bovine Corneal
Endothelial Cells. WKU Student Research Conference. Undergraduate Paper Session 6:
Natural Sciences.
Farmer B, Murray R, Khundmiri S. Cardioglycoside stimulated association between NaK-ATPase and NHE-1 : A TIRF and FRET Analysis. KAS 2012 Annual Meeting.
Undergraduate Poster Session. 20 Oct 2012.
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